A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
Absence or reduced levels of PROTHROMBIN in the blood.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Activated form of factor V. It is an essential cofactor for the activation of prothrombin catalyzed by factor Xa.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
Laboratory tests for evaluating the individual's clotting mechanism.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
Found in various tissues, particularly in four blood-clotting proteins including prothrombin, in kidney protein, in bone protein, and in the protein present in various ectopic calcifications.
A nutritional condition produced by a deficiency of VITAMIN K in the diet, characterized by an increased tendency to hemorrhage (HEMORRHAGIC DISORDERS). Such bleeding episodes may be particularly severe in newborn infants. (From Cecil Textbook of Medicine, 19th ed, p1182)
System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Agents that prevent clotting.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.
Agents that cause clotting.
Triple-looped protein domains linked by disulfide bonds. These common structural domains, so-named for their resemblance to Danish pastries known as kringlers, play a role in binding membranes, proteins, and phospholipids as well as in regulating proteolysis. Kringles are also present in coagulation-related and fibrinolytic proteins and other plasma proteinases.
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.
The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
Formation and development of a thrombus or blood clot in the blood vessel.
Physiologically inactive substances that can be converted to active enzymes.
Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
The formation or presence of a blood clot (THROMBUS) within a vein.
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
Enzymes that catalyze the joining of two molecules by the formation of a carbon-carbon bond. These are the carboxylating enzymes and are mostly biotinyl-proteins. EC 6.4.
The natural enzymatic dissolution of FIBRIN.
Solutions or mixtures of toxic and nontoxic substances elaborated by snake (Ophidia) salivary glands for the purpose of killing prey or disabling predators and delivered by grooved or hollow fangs. They usually contain enzymes, toxins, and other factors.
Compounds that contain a 1-dimethylaminonaphthalene-5-sulfonyl group.
The rate dynamics in chemical or physical systems.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.
Bleeding or escape of blood from a vessel.
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
Venoms from snakes of the family Elapidae, including cobras, kraits, mambas, coral, tiger, and Australian snakes. The venoms contain polypeptide toxins of various kinds, cytolytic, hemolytic, and neurotoxic factors, but fewer enzymes than viper or crotalid venoms. Many of the toxins have been characterized.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
Substances found in many plants, containing the 4-hydroxycoumarin radical. They interfere with vitamin K and the blood clotting mechanism, are tightly protein-bound, inhibit mitochondrial and microsomal enzymes, and are used as oral anticoagulants.
Venoms from SNAKES of the viperid family. They tend to be less toxic than elapid or hydrophid venoms and act mainly on the vascular system, interfering with coagulation and capillary membrane integrity and are highly cytotoxic. They contain large amounts of several enzymes, other factors, and some toxins.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.
Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
A genus of poisonous snakes of the VIPERIDAE family. About 50 species are known and all are found in tropical America and southern South America. Bothrops atrox is the fer-de-lance and B. jararaca is the jararaca. (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, p336)
Method of tissue preparation in which the tissue specimen is frozen and then dehydrated at low temperature in a high vacuum. This method is also used for dehydrating pharmaceutical and food products.
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens).
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C.
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.
A deficiency of blood coagulation factor V (known as proaccelerin or accelerator globulin or labile factor) leading to a rare hemorrhagic tendency known as Owren's disease or parahemophilia. It varies greatly in severity. Factor V deficiency is an autosomal recessive trait. (Dorland, 27th ed)

Evidence suggesting the regulation of a coagulation factor levels in rabbits by a transferable plasma agent. (1/1307)

New Zealand white rabbits were given 30 ml of goat serum intravenously. This procedure resulted in an immediate decrease in platelet count, fibrinogen, and levels of coagulation factors II, V, VII, and X, due to consumption coagulopathy. These factors returned toward baseline levels approximately 12 hr after the injection. Plasma from rabbits who had received goat serum 48 hr previously (donor rabbits) was injected into recipient rabbits. This procedure resulted in a slight rise in the level of coagulation factor II (range, 20%-30%) and a significant rise in factors V (35%-75%), VII (35%-235%), and X (35%-75%) in the recipients. When plasma from control donor rabbits who had not received goat serum was injected into recipients, there was no change in these coagulation factors. It is postulated that the reduction in coagulation factor levels in donor rabbits induces a "coagulopoietin" for each factor or one "coagulopoietin" for all factors which stimulates increased synthesis and/or release of these factors in recipient rabbits.  (+info)

Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. (2/1307)

The reported incidence of thromboembolism in children with acute lymphoblastic leukemia (ALL) treated with L-asparaginase, vincristine, and prednisone varies from 2.4% to 11.5%. The present study was designed to prospectively evaluate the role of the TT677 methylenetetrahydrofolate reductase (MTHFR) genotype, the prothrombin G20210A mutation, the factor V G1691A mutation, deficiencies of protein C, protein S, antithrombin, and increased lipoprotein (a) concentrations in leukemic children treated according to the ALL-Berlin-Frankfurt-Muenster (BFM) 90/95 study protocols with respect to the onset of vascular events. Three hundred and one consecutive leukemic children were enrolled in this study. Fifty-five of these 301 subjects investigated had one established single prothrombotic risk factor: 20 children showed the TT677 MTHFR genotype; 5 showed the heterozygous prothrombin G20210A variant; 11 were carriers of the factor V G1691A mutation (heterozygous, n = 10; homozygous, n = 1); 4 showed familial protein C, 4 protein S, and 2 antithrombin type I deficiency; 9 patients were suffering from familially increased lipoprotein (a) [Lp(a)] concentrations (>30 mg/dL). In addition, combined prothrombotic defects were found in a further 10 patients: the FV mutation was combined with the prothrombin G20210A variant (n = 1), increased Lp(a) (n = 3), protein C deficiency (n = 1), and homozygosity for the C677T MTHFR gene mutation (n = 1). Lp(a) was combined with protein C deficiency (n = 2) and the MTHFR TT 677 genotype (n = 2). Two hundred eighty-nine of the 301 patients were available for thrombosis-free survival analysis. In 32 (11%) of these 289 patients venous thromboembolism occurred. The overall thrombosis-free survival in patients with at least one prothrombotic defect was significantly reduced compared with patients without a prothrombotic defect within the hemostatic system (P <.0001). In addition, a clear-cut positive correlation (P <.0001) was found between thrombosis and the use of central lines. However, because the prothrombotic defects diagnosed in the total childhood population studied were all found within the prevalences reported for healthy Caucasian individuals, the interaction between prothrombotic risk factors, ALL treatment, and further environmental factors is likely to cause thrombotic manifestations.  (+info)

G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. (3/1307)

BACKGROUND: A single base pair mutation in the prothrombin gene has recently been identified that is associated with increased prothrombin levels. Whether this mutation increases the risks of arterial and venous thrombosis among healthy individuals is controversial. METHODS AND RESULTS: In a prospective cohort of 14 916 men, we determined the prevalence of the G20210A prothrombin gene variant in 833 men who subsequently developed myocardial infarction, stroke, or venous thrombosis (cases) and in 1774 age- and smoking status-matched men who remained free of thrombosis during a 10-year follow-up (control subjects). Gene sequencing was used to confirm mutation status in a subgroup of participants. Overall, carrier rates for the G20210A mutation were similar among case and control subjects; the relative risk of developing any thrombotic event in association with the 20210A allele was 1.05 (95% CI, 0.7 to 1.6; P=0.8). We observed no evidence of association between mutation and myocardial infarction (RR=0.8, P=0.4) or stroke (RR=1.1, P=0.8). For venous thrombosis, a modest nonsignificant increase in risk was observed (RR=1.7, P=0.08) that was smaller in magnitude than that associated with factor V Leiden (RR=3.0, P<0. 001). Nine individuals carried both the prothrombin mutation and factor V Leiden (5 controls and 4 cases). One individual, a control subject, was homozygous for the prothrombin mutation. CONCLUSIONS: In a large cohort of US men, the G20210A prothrombin gene variant was not associated with increased risk of myocardial infarction or stroke. For venous thrombosis, risk estimates associated with the G20210A mutation were smaller in magnitude than risk estimates associated with factor V Leiden.  (+info)

Injury-induced gelatinase and thrombin-like activities in regenerating and nonregenerating nervous systems. (4/1307)

It is now widely accepted that injured nerves, like any other injured tissue, need assistance from their extracellular milieu in order to heal. We compared the postinjury activities of thrombin and gelatinases, two types of proteolytic activities known to be critically involved in tissue healing, in nonregenerative (rat optic nerve) and regenerative (fish optic nerve and rat sciatic nerve) neural tissue. Unlike gelatinases, whose induction pattern was comparable in all three nerves, thrombin-like activity differed clearly between regenerating and nonregenerating nervous systems. Postinjury levels of this latter activity seem to dictate whether it will display beneficial or detrimental effects on the capacity of the tissue for repair. The results of this study further highlight the fact that tissue repair and nerve regeneration are closely linked and that substances that are not unique to the nervous system, but participate in wound healing in general, are also crucial for regeneration or its failure in the nervous system.  (+info)

Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. (5/1307)

The inherited thrombophilias--deficiencies of protein C, protein S, and antithrombin III--and the prothrombotic polymorphisms factor V G1691A and factor II G20210A predispose patients toward venous thromboembolism (VTE). The aim of this study was to determine the prevalence of single and combined prothrombotic factors in patients with idiopathic VTE and to estimate the associated risks. The study group consisted of 162 patients referred for work-up of thrombophilia after documented VTE. The controls were 336 consecutively admitted patients. In all subjects factor V G1691A, factor II G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T were analyzed by specific polymerase chain reactions and restriction enzymes. Activities of antithrombin III and protein C, free protein S antigen, and lupus anticoagulant were determined in a subset of 109 patients who were not receiving oral anticoagulants. The prevalences of heterozygotes and homozygotes for factor V G1691A and factor II G20210A among patients and controls were 40.1% versus 3.9% and 18.5% versus 5.4%, respectively (P=0.0001). The prevalence of homozygotes for MTHFR C677T in patients was 22.8% and in controls, 14.3% (P=0.025). Heterozygous and homozygous factor V G1691A, factor II G20210A, and homozygous MTHFR C677T were found to be independent risk factors for VTE, with odds ratios of 16.3, 3.6, and 2.1, respectively. Two or more polymorphisms were detected in 27 of 162 patients (16.7%) and in 3 of 336 controls (0.9%). Logistic regression analysis disclosed odds ratios of 58.6 (confidence interval [CI], 22.1 to 155.2) for joint occurrence of factor V and factor II polymorphisms, of 35.0 (CI, 14.5 to 84.7) for factor V and MTHFR polymorphisms, and of 7.7 (CI, 3.0 to 19.6) for factor II and MTHFR polymorphisms. Among 109 patients in whom a complete thrombophilic work-up was performed, 74% had at least 1 underlying defect. These data indicate that in most patients referred for evaluation of thrombophilia due to idiopathic VTE, 1 or more underlying genetic predispositions were discernible. The presence of >1 of the prothrombotic polymorphisms was associated with a substantial risk of VTE.  (+info)

Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. (6/1307)

Single-point mutations in the gene coding for prothrombin (factor II:A20210) or factor V (factor V:A1691) are associated with an increased risk of venous thromboembolism. The use of oral contraceptives is also a strong and independent risk factor for the disease, and the interaction between factor V:A1691 and oral contraceptives greatly increases the risk. No information is available about the interaction between oral contraceptives and mutant prothrombin. We investigated 148 women with a first, objectively confirmed episode of deep vein thrombosis and 277 healthy women as controls. Fourteen patients (9.4%) were carriers of factor II:A20210, 24 (16.2%) of factor V:A1691, and 4 (2.7%) of both defects. Among controls, the prevalence was 2.5% for either factor II:A20210 or factor V:A1691, and there was no carrier of both the mutations. The relative risk of thrombosis was 6-fold for factor II:A20210 and 9-fold for factor V:A1691. The most prevalent circumstantial risk factor in patients and the only one observed in controls was oral contraceptive use, which per se conferred a 6-fold increased risk of thrombosis. The risk increased to 16.3 and 20.0 when women with factor II:A20210 or factor V:A1691 who used oral contraceptives were compared with noncarriers and nonusers. These figures indicate a multiplicative interaction between the genetic risk factors and oral contraceptives. No difference in the type of oral contraceptives was observed between patients and controls, those of third generation being the most frequently used (73% and 80%). We conclude that carriers of the prothrombin mutation who use oral contraceptives have a markedly increased risk of deep vein thrombosis, much higher than the risk conferred by either factor alone.  (+info)

Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. (7/1307)

Several recent studies evaluated a possible effect of the prothrombotic polymorphisms such as 5,10 methylenetetrahydrofolate reductase (MTHFR) nt 677C --> T, factor V (F V) nt 1691G --> A (F V Leiden), and factor II (F II) nt 20210 G --> A on the risk of myocardial infarction. In the present study, we analyzed the effect of these prothrombotic polymorphisms, as well as apolipoprotein (Apo) E4, smoking, hypertension, diabetes mellitus, and hypercholesterolemia, on the risk of myocardial infarction in young males. We conducted a case-control study of 112 young males with first acute myocardial infarction (AMI) before the age of 52 and 187 healthy controls of similar age. The prevalences of heterozygotes for F V G1691A and F II G20210A were not significantly different between cases and controls (6.3% v 6.4% and 5.9% v 3.4% among cases and controls, respectively). In contrast, the prevalence of MTHFR 677T homozygosity and the allele frequency of Apo E4 were significantly higher among patients (24.1% v 10.7% and 9.4% v 5.3% among cases and controls, respectively). Concomitant presence of hypertension, hypercholesterolemia, or diabetes and one or more of the four examined polymorphisms increased the risk by almost ninefold (odds ratio [OR] = 8.66; 95% confidence interval [CI], 3.49 to 21.5) and concomitant smoking by almost 18-fold (OR = 17.6; 95% CI, 6.30 to 48.9). When all atherogenic risk factors were analyzed simultaneously by a logistic model, the combination of prothrombotic and Apo E4 polymorphisms with current smoking increased the risk 25-fold (OR = 24.7; 95% CI, 7.17 to 84.9). The presented data suggest a synergistic effect between atherogenic and thrombogenic risk factors in the pathogenesis of AMI, as was recently found in a similar cohort of women.  (+info)

Thrombophilia as a multigenic disease. (8/1307)

BACKGROUND AND OBJECTIVE: Venous thrombosis is a common disease annually affecting 1 in 1000 individuals. The multifactorial nature of the disease is illustrated by the frequent identification of one or more predisposing genetic and/or environmental risk factors in thrombosis patients. Most of the genetic defects known today affect the function of the natural anticoagulant pathways and in particular the protein C system. This presentation focuses on the importance of the genetic factors in the pathogenesis of inherited thrombophilia with particular emphasis on those defects which affect the protein C system. INFORMATION SOURCES: Published results in articles covered by the Medline database have been integrated with our original studies in the field of thrombophilia. STATE OF THE ART AND PERSPECTIVES: The risk of venous thrombosis is increased when the hemostatic balance between pro- and anti-coagulant forces is shifted in favor of coagulation. When this is caused by an inherited defect, the resulting hypercoagulable state is a lifelong risk factor for thrombosis. Resistance to activated protein C (APC resistance) is the most common inherited hypercoagulable state found to be associated with venous thrombosis. It is caused by a single point mutation in the factor V (FV) gene, which predicts the substitution of Arg506 with a Gln. Arg506 is one of three APC-cleavage sites and the mutation results in the loss of this APC-cleavage site. The mutation is only found in Caucasians but the prevalence of the mutant FV allele (FV:Q506) varies between countries. It is found to be highly prevalent (up to 15%) in Scandinavian populations, in areas with high incidence of thrombosis. FV:Q506 is associated with a 5-10-fold increased risk of thrombosis and is found in 20-60% of Caucasian patients with thrombosis. The second most common inherited risk factor for thrombosis is a point mutation (G20210A) in the 3' untranslated region of the prothrombin gene. This mutation is present in approximately 2% of healthy individuals and in 6-7% of thrombosis patients, suggesting it to be a mild risk factor of thrombosis. Other less common genetic risk factors for thrombosis are the deficiencies of natural anticoagulant proteins such as antithrombin, protein C or protein S. Such defects are present in less than 1% of healthy individuals and together they account for 5-10% of genetic defects found in patients with venous thrombosis. Owing to the high prevalence of inherited APC resistance (FV:Q506) and of the G20210A mutation in the prothrombin gene, combinations of genetic defects are relatively common in the general population. As each genetic defect is an independent risk factor for thrombosis, individuals with multiple defects have a highly increased risk of thrombosis. As a consequence, multiple defects are often found in patients with thrombosis.  (+info)

TY - JOUR. T1 - Staphylocoagulase-binding region in human prothrombin. AU - Kawabata, Shun-Ichiro. AU - Morita, Takashi. AU - Iwanaga, Sadaaki. AU - Igarashi, Hideo. PY - 1985/1/1. Y1 - 1985/1/1. N2 - A staphylocoagulase-binding region in human prothrombin was studied by utilizing several fragments prepared from prothrombin by limited proteolysis. Bovine prothrombin, prethrombin 1, prethrombin 2, and human diisopropylphosphorylated α-thrombin strongly inhibited formation of the complex (staphylothrombin) between human prothrombin and staphylocoagulase, but bovine prothrombin fragment 1 and fragment 2 had no effect on the complex formation, indicating that the binding region of human prothrombin for staphylocoagulase is located in the prethrombin 2 molecule. To identify further the staphylocoagulase-binding region, human α-thrombin was cleaved into the NH2-terminal large fragment (Mr = 26, 000) and the COOH-terminal fragment (Mr = 16,000) by porcine pancreatic elastase. Of these fragments, ...
Prothrombin (Factor II) G20210A mutation is associated with elevated prothrombin levels. Individuals heterozygous for this mutation have an estimated 3-8 fold increased risk for venous thrombosis. The G20210A mutation has an overall prevalence of up to 3% in the Caucasian population, but it is rarely seen in other ethnic groups.. Analysis for the prothrombin G20210A mutation is offered as a specific DNA test, or as part of a thrombophilia panel (see Thrombosis panel) which also includes the factor V Leiden analysis. 8-14% of G20210A heterozygotes have other inherited thrombophilic disorders. Individuals with multiple thrombophilic mutations develop venous thromboembolism at a younger age and are at higher risk for recurrent thrombosis than those with a single defect.. ...
Introduction Thrombophilia is clinical tendency to develop thrombosis. Amutation in the gene encoding coagulation factor V is a common geneticpredisposition to venous thrombosis. A second common genetic risk isprothrombin gene mutation, the G20210A variation associated with elevatedplasma prothrombin levels and increased risk of thrombosis. (1) Furthermore,Protein S deficiency is a rare condition that can lead to DVT.. (2) We presentto you a case of multifactorial hemophilia with a heterozygous prothrombin genemutation, factor V Leiden deficiency, and protein s deficiency. Clinical case:A 48 Years old Saudi man knowing Case of DM, Dyslipidemiawas admitted to our hospital because of left leg swelling after long travel for10 hours. He had the previous history of DVT for 4 years. It was investigatedand he had factor v laden deficiency that confirmed by PCR Assay and he startedwarfarin but he stopped it after 10 months. he had no previous surgery norfamily history or active cancer. On examination, ...
TY - JOUR. T1 - Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma. AU - Chieh, Jen Jie. AU - Huang, K. W.. AU - Chuang, C. P.. AU - Wei, W. C.. AU - Dong, J. J.. AU - Lee, Y. Y.. N1 - Funding Information: This work was supported by the National Science Council of Taiwan under Grant NSC100-2221-E003-013, Grant NSC 103-2923-M-003-002-, Grant NSC 103-2112-M-003-010, the Ministry of Health and Welfare under Grant MOHW103-TDU-N-211-133002, Aim for the Top University Plan of the National Taiwan Normal University, and the Ministry of Education, Taiwan, under Grant 103J1A27.. PY - 2016/8. Y1 - 2016/8. N2 - The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial ...
The prothrombin gene variant resulting form a G--,A transition at position 20210 has been described as a common genetic risk factor for venous thrombosis. However, the risk for developing arterial disease is unknown. In this investigation, we studied 116 patients with venous thrombosis and 71 with arterial disease, all of whom were compared with 295 controls. Additionally, we also investigated the distribution of the prothrombin alleles among African descendents and Amazonian Indians from Brazil. The prevalence of 0.7% for 20210A allele in the control group increased to 4.3% (P = 0.021) among patients with venous thrombosis. There was also a high prevalence of the mutated allele in a selected arterial disease group (5.7%) without hyperlipoproteinemia, hypertension, and diabetes mellitus when compared to the controls (P = 0.013). Heterozygotes for the allele 20210A were common among individuals of African descent (2%) and rare among Indians. These data support the hypothesis that the prothrombin ...
Nakao, A and Virji, A and Iwaki, Y and Carr, B and Iwatsuki, S and Starzl, E (1991) Abnormal prothrombin (DES-y-Carboxy Prothrombin) in hepatocellular carcinoma. Hepato-Gastroenterology, 38. 450 - 453. ISSN 0172-6390 ...
My recent CBC showed prothrombin level (PT) is low (1 in a reference range of 2-3). Previous test in 2004 showed normal level. I understand that this means blood clots too slowly and is sometimes cau...
The variant causes elevated plasma prothrombin levels (hyperprothrombinemia),[4] possibly due to increased pre-mRNA stability.[5] Prothrombin is the precursor to thrombin, which plays a key role in causing blood to clot (blood coagulation). G20210A can thus contribute to a state of hypercoagulability, but not particularly with arterial thrombosis.[4] A 2006 meta-analysis showed only a 1.3-fold increased risk for coronary disease.[6] Deficiencies in the anticoagulants Protein C and Protein S further increase the risk five- to tenfold.[2] Behind non-O blood type[7] and factor V Leiden, prothrombin G20210A is one of the most common genetic risk factors for VTE.[4] Increased production of prothrombin heightens the risk of blood clotting. Moreover, individuals who carry the mutation can pass it on to their offspring.[8] The mutation increases the risk of developing deep vein thrombosis (DVT),[9] which can damage veins throughout the body, causing pain and swelling and sometimes leading to ...
Sales, means the sales volume of Human Prothrombin Complex Revenue, means the sales value of Human Prothrombin Complex This report studies sales (consumption) of Human Prothrombin Complex in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Baxter CSL Bayer Grifols Octapharma Shanghai RAAS Hualan Bio
In March 2006 I began experiencing pain in my right jaw and neck. An ultrasound of my thyroid showed a mild enlargement of my thyroid gland and thrombosis of the right internal jugular. A CT was ordered which showed bilateral segmental pulmonary emboli. A work up done to rule out cancer was negative however blood work showed a prothrombin gene mutation. At the time I was taking Yasmin. I was placed on Coumadin and told I should stay on this forever. I am worried that the risk of a bleed may now outweigh the need for anticoagulation since the thyroiditis is controlled and I am off oral contraceptives. Would it be wise to stop the Coumadin or is long-term use still recommended? Thank you ...
Looking for Prothrombin g20210a mutation? Find out information about Prothrombin g20210a mutation. see blood clotting blood clotting, process by which the blood coagulates to form solid masses, or clots. In minor injuries, small oval bodies called... Explanation of Prothrombin g20210a mutation
Although the prevalence of G20210A prothrombin gene mutation was higher among our CAD patients than among control subjects, this difference did not reach statistical significance. Similarly, we found no difference in distribution of genotypes between CAD patients with or without previous MI. These results provide evidence against a major role for G20210A mutation as a risk factor for either CAD or MI, at least in the present study conditions.. Previous data are controversial. Some authors have reported observations consistent with ours20 21 22 23 24 25 26 27 ; in particular, the only prospective study published so far found no association between the 20210A allele and the risk of MI.18 However, caution in the interpretation of the results of that study has been suggested,11 mainly because of the procedures used for end-point validation, which were considered inappropriate for ensuring the quality of controls. Furthermore, because of the high heterogeneity of the population observed, these ...
Snake prothrombin activator that attacks the hemostatic system of prey. This catalytic subunit is functionally similar to blood coagulation factor Xa. It requires a non-catalytic subunit present in the venom, which is similar to coagulation factor Va, to be fully active (By similarity).
Please click on the Lab Form Link in the Forms Section to print and complete the Genetic Test Requisition Form. Submission of completed Genetic Test Requisition Form is required, and submission of informed consent form is recommended (but not required).. This test is a targeted mutation analysis that detects presence of the 20210G,A (also known as G20210A or c.*97G,A) pathogenic mutation in the Factor 2 (F2) gene and can determine whether this mutation is present in heterozygous or homozygous state in a patient. The F2 gene encodes coagulation Factor II, also known as prothrombin, protein. The presence of 20210G,A mutation in the F2 gene increases the patients risk for prothrombin-related thrombophilia, which is characterized by venous thromboembolism (VTE) that manifest most commonly in adults and is associated with elevated prothrombin levels.. ...
TY - JOUR. T1 - Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis. AU - Kremers, Romy M. W.. AU - Kleinegris, Marie-Claire. AU - Ninivaggi, Marisa. AU - de Laat, Bas. AU - ten Cate, Hugo. AU - Koek, Ger H.. AU - Wagenvoord, Rob J.. AU - Hemker, H. Coenraad. PY - 2017/5/4. Y1 - 2017/5/4. KW - MOLECULAR-WEIGHT HEPARIN. KW - CONVENTIONAL COAGULATION TESTS. KW - HEPATITIS-C PATIENTS. KW - PROTEIN-C. KW - VENOUS THROMBOEMBOLISM. KW - CLINICAL CONSEQUENCES. KW - PLASMA. KW - DISEASE. KW - COAGULOPATHY. KW - INHIBITION. U2 - 10.1371/journal.pone.0177020. DO - 10.1371/journal.pone.0177020. M3 - Article. C2 - 28472132. VL - 12. JO - PLOS ONE. JF - PLOS ONE. SN - 1932-6203. IS - 5. M1 - 0177020. ER - ...
Koppaka, V.; Wang, J.; Banerjee, M.; Lentz, B.R., 1996: Soluble phospholipids enhance factor Xa-catalyzed prothrombin activation in solution
The formation of a blood clot depends on a number of proteins found within plasma called clotting factors. Normally the clotting factors are inactive and do not cause clotting. Following injury however, the clotting factors are activated to produce a clot. This is a complex process involving chemical reactions, but it can be summarized in 3 main stages; the chemical reactions can be stated in two ways: just as with platelets, the contact of inactive clotting factors with exposed connective tissue can result in their activation. Chemicals released from injured tissues can also cause activation of clotting factors. After the initial clotting factors are activated, they in turn activate other clotting factors. A series of reactions results in which each clotting factor activates the next clotting factor in the series until the clotting factor prothrombin activator is formed. Prothrombin activator acts on an inactive clotting factor called prothrombin. Prothrombin is converted to its active form ...
|p||strong|Prothrombin|/strong| (coagulation factor II) (H2N-Tyr-Ile-His-Pro-OH) is produced in the liver and is post-translationally modified in a vitamin K-dependent reaction that converts ten glutamic acids on prothrombin into gamma-carboxyglutamic aci
This page includes the following topics and synonyms: Prothrombin Complex Concentrate, Prothrombin Drug Combination, PCC, Beriplex, Octaplex, Kcentra, Cofact.
Prothrombin fragment F1+2 aids in the risk assessment of thrombosis and efficacy of anticoagulant treatment monitoring. Now for the first time, LOCI® technology* is being used to deliver an improved testing method for the measurement of F1+2.
Buy our Natural Human Prothrombin protein. Ab62502 is a protein fragment produced in Nativesyntheticaly and has been validated in FuncS, SDS-PAGE. Abcam…
Literature References: Mol wt 69,000-74,000. Coagulation proenzyme present in highest concentration in blood. Prothrombin is one of the vitamin-K dependent blood coagulation factors. It is converted to thrombin by the action of factor Xa, factor V and phospholipid in the presence of Ca2+ ions. Accounts for , 0.2% of total plasma protein. Prepn of human and bovine prothrombin: Goldstein et al., J. Biol. Chem. 234, 2857 (1959); Lanchantin et al., ibid. 238, 238 (1963). Chemistry of activation: Magnussen, Biochem. J. 115, 2P (1969). Synthesized normally by liver parenchymal cells in a cyclic asynchronous manner. Dicoumarol derivatives halt the synthesis, while vitamin K1 stimulates synchronized activity of all the liver parenchymal cells: Barnhart, Anderson, Biochem. Pharmacol. 9, 23 (1962). The glycoprotein structure probably consists of a single polypeptide chain containing between 8 and 10% carbohydrate: Magnussen, Thromb. Diath. Haemorrh. suppl. 54, 31 (1973). Reviews: W. H. Seegers, ...
Caution should be exercised when anticoagulants are given in conjunction with Atromid-S. Usually, the dosage of the anticoagulant should be reduced by one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications. Frequent prothrombin determinations are advisable until it has been determined definitely that the prothrombin level has been stabilized.. Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites. Caution should be exercised when treating patients with either of these drugs or other highly protein-bound drugs and Atromid-S. The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.. Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months. For these reasons, it is felt that, in most subjects who have had an ...
Caution should be exercised when anticoagulants are given in conjunction with Atromid-S. Usually, the dosage of the anticoagulant should be reduced by one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications. Frequent prothrombin determinations are advisable until it has been determined definitely that the prothrombin level has been stabilized.. Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites. Caution should be exercised when treating patients with either of these drugs or other highly protein-bound drugs and Atromid-S. The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.. Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months. For these reasons, it is felt that, in most subjects who have had an ...
[106 Pages Report] Check for Discount on Global Prothrombin Complex Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 report by Global Info Research. Market Overview The global Prothrombin Complex market size is expected...
Human prothrombin IgA ELISA kit is an in-vitro quantitative method for detecting levels of IgA autoantibodies to prothrombin in human plasma and serum.
Purpose: We have previously reported local persistent hypercoagulability six months after sirolimus-eluting stent (SES) implantation by measuring plasma prothrombin fragment F1+2 (frF1+2) levels. The aims of this study are to examine the relationship between time-dependent changes of local vascular response and angiographic peri-stent contrast staining (PSS) following zotarolimus-eluting stent (ZES), SES, and bare-metal stent (BMS) implantation.. Methods: Eighty-five patients treated five years earlier with coronary stenting, with no evidence of restenosis, were studied [ZES: 20, SES: 35, and BMS: 30]. We measured the levels of frF1+2 and pentraxin3 (PTX3) from the coronary sinus (CS) and sinus of Valsalva (V) 6 months (6M) and 5 years (5Y) after stent implantation. The transcardiac gradient (Δ) was defined as the CS levels minus V levels. The occurrence rate of PSS was evaluated and compared among ZES, SES, and BMS groups.. Results: The ΔfrF1+2 (6M) was smaller in the ZES or BMS group than in ...
A novel process for the determination of prothrombin in biological material, by conversion of prothrombin into thrombin, enzymatic fission of a thrombin substrate and measurement of a fission product,
The deficiency of vitamin K in the body can trigger the problems of coagulation, which is very uncommon in people. Moreover, the level of prothrombin below the 20% is another bad symptom; it aggravates the chances of spontaneous gingival hemorrhages that can disturb the dental formation in a negative way. Another cause is gingival is bleeding, especially after the brushing of the teeth or when prothrombin level falls down to the 35%. This affects the normal development of teeth and gums, which are considered normal for the oral hygiene. Furthermore, the deficiency of vitamin K can cause serious gums diseases by affecting the dental health. Hence, the role of a dentist is crucial in guiding people to avoid this deficiency in them ...
Commander Prothrombin kit ELISA pour beaucoup de réactivité. Poulet, Boeuf (Vache), Chien et plus. Comparez Prothrombin kit ELISA et trouvez le bon produit chez anticorps-enligne.fr.
Results 45 patients were treated with PCC and included in the analysis. Mean patient age was 59.64 years, 42.2% were women and 57.77% men. The average dose was 1604 IU, the global survival after seven days was 73.33% and 35.55% had concomitant treatment with fibrinogen.. 11.11% of the patients had been treated with oral anticoagulants (OAT) prior to the emergency bleeding,. 48.89% had polytraumatic wounds,. 4.44% had thrombocytopenia secondary to hepatopathy,. 0% had haemophilia,. 75.55% had an active haemorrhage,. 68.89% underwent surgery, when the PCC was administered.. Quick time (s) (% // INR):. ...
Detailed drug Information for prothrombin complex human Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
ANSWER: Prothrombin activator formed by intrinsic and extrinsic systems, converts prothrombin to thrombin which converts fibrinogen to fibrin which forms a clot with platelets ...
And every male among you who is eight days old shall be circumcised throughout your generations... Genesis 17:12 Prothrombin is a plasma protein involved in the blood clotting process. Specifically it is the precursor of the enzyme thrombin, which catalyzes the final step of the clotting process ( Vitamin K along with calcium is needed…
BioAssay record AID 813331 submitted by ChEMBL: Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 125/6.
BioAssay record AID 814159 submitted by ChEMBL: Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 98/5.
Prothrombin time is a measure of blood clotting function. More than likely, the changes from normal to abnormal and back to normal in an otherwise healthy person or someone with only mild liver...
Gentaur molecular products has all kinds of products like :search , Molecular Innovations \ Sheep Anti Mouse Prothrombin IgG fraction \ SASMPT-GF for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , Molecular Innovations \ Sheep Anti Mouse Prothrombin antiserum \ SASMPT for more molecular products just contact us
Prothrombin activation is a key reaction of blood coagulation. The enzyme (factor Xa), the cofactor (factor Va), and substrate of this reaction all bind to memb...
2) under optimised therapy were randomised to supplementation with 1g/day or 4 g/day n3-PUFA, or placebo for 12 weeks. Using whole-blood flow cytometry, monocyte-platelet aggregates characterised by CD14+/CD42b+ co-expression and monocytic tissue factor (TF) were determined. Plasma levels of P-selectin, sCD40L, fibrinogen, prothrombin fragment F1.2, TF and pro-inflammatory markers (high sensitive[hs] interleukin-6, hsCRP, hsTNF-alpha, monocyte chemotactic protein-1) were measured by immunoassay ...
Looking for online definition of serum prothrombin conversion accelerator in the Medical Dictionary? serum prothrombin conversion accelerator explanation free. What is serum prothrombin conversion accelerator? Meaning of serum prothrombin conversion accelerator medical term. What does serum prothrombin conversion accelerator mean?
There are many genetic and acquired risk factors that are known to cause venous thromboembolic disorders (VTE). One of these is the Prothrombin G20210A mutation, which has been identified in 1996. Prothrombin G20210A mutation causes higher levels of the clotting factor prothrombin in the blood of carriers, which creates a higher tendency towards blood clotting (hypercoagulability), and therefore the carriers become at higher risk of developing VTE. High prevalence of Prothrombin G20210A mutation was reported in Caucasian populations, but the prevalence was almost absent in non-Caucasians. That was most obvious in countries of South Europe and the Mediterranean region. This review article discusses Prothrombin G20210A mutation, how it causes VTE, the origin of the mutation, and its distribution worldwide with special concentration on the Mediterranean area.. ...
Looking for online definition of prothrombin test in the Medical Dictionary? prothrombin test explanation free. What is prothrombin test? Meaning of prothrombin test medical term. What does prothrombin test mean?
The procoagulant proteases present in Russells Viper venom (RVV) are responsible for promoting consumption coagulopathy in victims. In this study, a procoagulant metalloprotease (Rusviprotease) possessing prothrombin activating and α-fibrinogenase properties has been purified and characterized from RVV. Rusviprotease is a 26.8 kDa glycoprotein which also exists in other multimeric forms. The peptide mass fingerprinting and secondary structure analyses of Rusviprotease revealed its similarity with snake venom prothrombin activators and metalloproteases. Similar to group A prothrombin activators, Rusviprotease cleaved prothrombin independent of any co-factor requirement generating meizothrombin which is further cleaved to form thrombin. The Km and Vmax values of Rusviprotease towards prothrombin were determined to be 1.73 μM, and 153.5 nM thrombin generated/min/μmoles of Rusviprotease, respectively. The Km and Vmax values of Rusviprotease towards fibrinogen were calculated to be 3.14 μM and ...
High doses of norethisterone in 70 Asian women treated for endometriosis were found to affect the blood coagulation factors as well as the cellular components of the blood. Fibrinogen level was found to be decreased (p < 0.01). Prothrombin increased significantly (p < 0.001) during the initial three months medication, after which it gradually reverted to baseline values at nine months. Factor V and X were significantly increased throughout the period of therapy (p<0.001) whilst factor VIII showed no change. This is evidence that coagulation factors from the liver are affected by norethisterone whilst that from the vascular endothelium is not. The changes in coagulation factors resulted in a shortened prothrombin time and kaolin cephalin time in the initial period of treatment reflecting the initial increase in prothrombin level. Jaundice occurred in three patients when their prothrombin levels were at their highest for the individual patient. The adjustment and return baseline levels ...
To ascertain the heterogeneity of anti-prothrombin antibodies (aPT), we compared three in-house aPT ELISAs: A) medium binding plates, phosphatidylserine, prothrombin, Tris-buffered saline, calcium; B) high binding plates, prothrombin, Tris-buffered saline; and C) high binding plates, prothrombin, PBS. One serum, exhibiting high positive aPT in all three ELISAs, was selected as the calibrator. Sera from 47 patients (41 with SLE, 4 with pAPS, 2 with arterial thromboses) were tested for IgG and IgM aPT.. The results showed six different patterns: 1) similar results were obtained with A, B and C (similar analytical sensitivity); 2) similar results were obtained with A and B while C showed lower analitycal sensitivity; 3) B and C seemed analytically less sensitive than A; 4) A and B were analytically less sensitive than C; 5) A showed very low analytical sensitivity; 6) A and C showed lower analytical sensitivity than B.. The analysis of all the presented patterns showed noncomparable results of the ...
Supplementary MaterialsS1 Methods: Detailed explanation of prekallikrein production and prothrombin/factor X lacking plasma assays. Aliquots of 10 L PD184352 ic50 had been taken and generated kallikrein enzymatic activity was determined using the specific chromogenic substrate S2302 (2 mM). The kinetics of p-nitroaniline formation were monitored at 405 nm and curves are representative data from at least three independent experiments. Inset shows the dose-response curve. The amounts of plasma derived kallikrein generated by LOBE was estimated using a calibration curve made with known concentrations of purified kallikrein and thus expressed as pmol of equivalent kallikrein/mL/min.(TIF) pntd.0007197.s004.tif (459K) GUID:?7403B6A2-C7C2-4032-B696-330A483F7AED S4 Fig: LOBE-induced kallikrein generation in factor X and prothrombin deficient PD184352 ic50 plasma. To further confirm LOBE-induced kallikrein activation specificity, the main procoagulant factors, FX and prothrombin (PThr), were depleted ...
Molecules containing the 33-kDa plasma protein alpha1-microglobulin were isolated from human plasma by anti-(alpha1-microglobulin) affinity chromatography. Five major bands could be seen after electrophoretic separation of the alpha1-microglobulin-containing proteins under native conditions. Immunoblotting demonstrated alpha1-microglobulin in all five bands. Two of these have been described previously: free alpha1-microglobulin and alpha1-microglobulin complexed with IgA (IgA x alpha1-microglobulin). The other three bands were identified as prothrombin alpha1-microglobulin, albumin x alpha1-microglobulin and dimeric alpha1-microglobulin. Prothrombin x alpha1-microglobulin were 1:2 and 1:1 complexes which carried approximately 1% of total alpha1-microglobulin, had molecular masses of about 145 kDa and 110 kDa upon SDS/PAGE and dissociated completely to free alpha1-microglobulin and prothrombin (72 kDa) when reducing agents were added, suggesting that the complexes were stabilized by disulfide ...
Individuals who carry the Factor V Leiden mutation have a 3- to 8-fold increased risk as heterozygotes and a greater than 10-fold increased risk as homozygotes. Individuals who carry the F2 prothrombin mutation have a 2- to 5-fold increased risk as heterozygotes and up to a 10-fold increased risk as homozygotes. Individuals who carry two copies of the 677C,T mutation, or one 677C,T and one 1298A,C mutation, in the MTHFR gene have between a 2- and 8-fold increased risk. Compound heterozygotes (heterozygous for more than one of the mutations tested for) have an even higher risk of thrombophilia. For example, a person that is heterozygous for both the Factor V Leiden mutation and heterozygous for the F2 prothrombin mutation has a greater than 20-fold increased risk ...
Prothrombin and thrombin are involved in diverse biological functions. The structure of prothrombin has been studied extensively and its cDNA has been cloned fr...
A prothrombin activity level of ~10% has been identified as the minimum level required for hemostasis per multiple national registries.27 However, to achieve and maintain hemostasis, FII troughs of 20% to 30% are recommended. The ideal method for replacement would be with a prothrombin concentrate. Unfortunately, prothrombin deficiency is one of the few RBDs without a dedicated factor concentrate for replacement.36 The mainstay of treatment for acute bleeding events or long-term prophylaxis remains prothrombin complex concentrates (PCC) or fresh frozen plasma (FFP).. FFP infusions at 15-20 ml/kg per dose can be used for acute bleeding and are expected to raise FII activity level by 25%.28 To maintain hemostasis in the post-surgical setting or in cases of severe bleeding, FFP at 3-10 ml/kg every 12-24 hours is advised to maintain safe and adequate correction.28,36,37 However the potential for volume overload with repeated FFP infusions could limit use in some patients with volume restrictions. ...
Thrombin (EC 3.4.21.5, fibrinogenase, thrombase, thrombofort, topical, thrombin-C, tropostasin, activated blood-coagulation factor II, blood-coagulation factor IIa, factor IIa, E thrombin, beta-thrombin, gamma-thrombin) is a serine protease, an enzyme that, in humans, is encoded by the F2 gene. Prothrombin (coagulation factor II) is proteolytically cleaved to form thrombin in the clotting process. Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, as well as catalyzing many other coagulation-related reactions. After the description of fibrinogen and fibrin, Alexander Schmidt hypothesised the existence of an enzyme that converts fibrinogen into fibrin in 1872. Thrombin is produced by the enzymatic cleavage of two sites on prothrombin by activated Factor X (Xa). The activity of factor Xa is greatly enhanced by binding to activated Factor V (Va), termed the prothrombinase complex. Prothrombin is produced in the liver and is ...
Professional guide for Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]. Includes: pharmacology, pharmacokinetics, contraindications, interactions, adverse reactions and more.
Prothrombin Time (PT)The TECHNOPLASTIN® HIS and TECHNOCLOT® PT Series are thromboplastin reagents derived from rabbit. Thromboplastins are a mixture of tissue factor, phospholipid, and calcium.The Prothrombin Time (PT) is used to:· Screen for congenital or acquired deficiencies in the extrinsic and common pathways· Monitor warfarin therapy· Aid in the diagnosis of DIC· Aid in
Clinical Significance Screening test for abnormalities of coagulation factors that are involved in the extrinsic pathway. Also used to monitor effects of Warfarin therapy and to study patients with hereditary and acquired clotting disorders.. Algorithms. Test FAQ. Prothrombin Time with INR. Alternative Name(s) PT. Prothrombin Time with INR Collection Guide. Return to Cardiology. Return to Virtual Test Guide. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the Payor being billed.. ...
Anti-Prothrombin antibody conjugated to Biotin validated for WB, IP, RIA, cELISA and tested in Human. Immunogen corresponding to full length native protein…
There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) on rivaroxaban or apixaban. We investigated the effectiveness of PCCs given for the management of MBEs in patients on rivaroxaban or apixaban. Between 1 January 2014 and 1 October 2016, we prospectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs. The effectiveness of PCCs was assessed by using the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria for the assessment of the effectiveness of major bleeding management. The safety outcomes were thromboembolic events and all-cause mortality within 30 days after treatment with PCCs. A total of 84 patients received PCCs for the reversal of rivaroxaban or apixaban due to a MBE. PCCs were given at a median (interquartile range) dose of 2000 IU (1500-2000 ...
Get accurate and quick report of Prothrombin Time Test in ghaziabad at your nearest Metropolis lab or your home at affordable cost. A Prothrombin time test is a test used to detect and diagnose bleeding disorder or clotting disorder in the body.
The Global Prothrombin Complex Concentrates Market is likely to gain traction due to the significant drop in demand for its counterpart fresh frozen plasma (FFP). PCC is available easily due to its lack of blood group specificity.
Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels. We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels. ...
Asymptomatic, nulliparous, heterozygous carriers of the prothrombin gene mutation are 3.6 times as likely as women who do not carry the mutation to experience severe pregnancy complications.
Acenocoumarol is an oral anticoagulant of the coumarin series, synthesized and developed in the Geigy laboratoires in the late 1960s and sold in the United States under the brand name of Sintrom. It lowers the prothrombin level of the blood. It is a white crystalline powder without taste and odor and has a molecular weight of 353. It is soluble in alkaline solutions but only slightly soluble in water and organic solvents. Chemically, acenocoumarol is 3-(alpha-acetonyl-4-nitrobenzyl)-4-hydroxycoumarin. ...
Aim of the work is to avoid vitamins and trace elements deficiency that commonly follow malabsorptve procedures and needs strict follow up for long times. Methods: The effect of our new procedure on different nutritional elements deficiency were evaluated from February 1999 to May 2005. They were 156 patients (122 females & 34 males) with mean age of 39.7 ? 9.2 and body mass index (BMI) 56 ? 22.1 and followed for six years till June 2011. For all patients excess weight loss, calcium, albumin, hemoglobin, iron, zinc, vitamin B12, and prothrombin concentration were done preoperatively three, six months and every year thereafter for six years ...
A one-stage prothrombin assay which measures the exponential rate of thrombin production in thromboplastin-treated, recalcified plasma. A serum reagent reduces the lag time before thrombin production substantially to zero for both normal and abnormal plasma, thus allowing measurements to be made in just a few minutes.
John Medical and Medical center Center in Detroit. Within an ACS news discharge, he said its important for doctors to replicate important information to patients following a colonoscopy, including that which was done, the full total results and tips for follow-up care. One helpful approach is to provide individuals with a document to collect and keep in their files. Another suggestion is to send the results right to the patients major care doctor. Typically, doctors who perform colonoscopies wont send [results] until the primary care doctor requests it, but I understand of centers that are being proactive about it and currently doing this, Alame said.We prepared reconstituted plasma by mixing prothrombin-deficient plasma with the recombinant prothrombins, since the probands plasma had not been suitable for evaluation due to warfarin treatment. We noticed that the mutant and wild-type prothrombins were fully converted to thrombins in a similar manner by prothrombinase within five minutes . ...
Question on "Lupus Anticoagulant Comp. A blood test returned with Dilute Prothrombin Time (DPT) 59.4 DPT Ratio 1.26. - Answered by a verified Doctor
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin) (ECLIPSE 03 ...
Thrombin antibody LS-C392770 is an unconjugated rabbit polyclonal antibody to human Thrombin (F2 / Prothrombin ). Validated for Peptide-ELISA and WB.
Thrombin antibody LS-C658904 is an unconjugated rabbit polyclonal antibody to human Thrombin (F2 / Prothrombin ). Validated for WB.
A prothrombin time (PT) test measures how long it takes for a clot to form in a blood sample. A clot is a thick lump of blood that the body produces to seal leaks, wounds, cuts, and scratches and prevent excessive bleeding.. The bloods ability to clot is a complex process involving platelets (also called thrombocytes) and proteins called clotting factors. Platelets are oval-shaped cells made in the bone marrow. Most clotting factors are made in the liver.. When a blood vessel breaks, platelets are first to the area to help seal the leak and temporarily stop or slow the bleeding. But for the clot to become strong and stable, the action of clotting factors is required.. The bodys clotting factors are numbered using the Roman numerals I through XII. They work together in a specialized sequence, almost like pieces of a puzzle. When the last piece is in place, the clot develops - but if even one piece is missing or defective, the clot cant form.. The PT test can be used to evaluate the action of ...
Covers prothrombin time and INR tests to measure how long it takes blood to clot. Explains why tests are done, how they differ, and how to prepare. Includes possible results and what they may mean. Looks at what may affect test results.
A prothrombin time test tells you how long it takes your blood to clot. Learn what it looks for, when you might need one, and what the results mean.
Biosystems prothrombin time (pt) Reagents are stable until the expiry date shown on the label when stored tightly closed and ifcontaminations are prevented
Find details on Hematology: prothrombin time in cats. Lab test paper including overview, sampling, tests, result data and more. All information is peer reviewed.
Prothrombin Antibody, IgG,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories client,medicine,medical supply,medical supplies,medical product
In October 2008, I had been unconscious for 2+ days, found unconscious by my son, rushed to the E.R., regained consciousness a few days later (but basically unable to move, etc), and was (finally!) diagnosed through an MRI of having had a stroke:eek:. Even though they run in my family, I was only 46, so the hematologist that I went to see a few months later determined that I had an inherited condition called prothrombin gene mutation(which basically means that your blood clots a lot more than the average person). I have been on coumadin (a blood thinner) since the time of the stroke and I have been in and out of the hospital for the blood being too thin too many times to count. Recently, I collapsed at my boyfriends house, and he rushed me to the hospital and I needed 5 units of blood and a few units of plasma(I weigh 110lbs). Since there was no external bleeding, after many tests, they determined that I had an ulcer and/or various very thin blood elsewhere in my body ...
A method for preparing a thromboplastin reagent from cultured human cells comprising the steps of washing the cells with isotonic aqueous salt solution, lysing the cells by hypotonic shock, and resuspending the cell lysate in a diluent compatible with a one-stage prothrombin time determination to reach a concentration of about 0.5 to 3.0 mg/mL thromboplastin, whereby the cell lysate thromboplastin suspension produces a clot in a one stage prothrombin time test in about 10 to 15 seconds, with a mean normal prothrombin time of about 11-13 seconds, when added to citrated normal plasma in a volume ratio of about 2:1, such thromboplastin reagent being stable for at least 8 hours at 37 C. and for at least 5 days at 4 C.
These tests become your new baseline that your doctor can refer too in the years ahead while monitoring your liver health.. Your baseline ultrasound should examine your liver and measure its portal vein (it should be under 12 mm) and spleen (it should be under 12 cm) to make sure its normal with no signs of cirrhosis or portal hypertension.. If you had cirrhosis before you cleared HBsAg: You need to be surveyed for liver cancer (with an ultrasound, alpha fetoprotein (AFP) blood test and a Des-gamma-carboxy prothrombin (DCP) test) every six months for at least five years, because cirrhosis puts you at high risk of liver cancer. Once an ultrasound finds no evidence of cirrhosis and all other tests are normal, including the cancer tests, then the testing can become less frequent and your doctor can prescribe a new monitoring schedule.. If youve had elevated liver enzymes (called ALT or SGPT) in the past, (higher than 19 in women and 30 in men), you need to continue to get tested every six ...
Andreas Groth1, Judi M ss2, Tine M ller3, Steen Ingwersen1. 1Biomodelling, 2Medical and Science, NovoSeven Key Projects, 3Biostatistics, Novo Nordisk, Bagsv rd, Denmark Objectives: NN1731 is a recombinant analogue of activated human coagulation factor FVII (FVIIa). Preclinical studies have indicated increased activity of NN1731 compared to native FVIIa in thrombin generation; a key step in the pathway to blood coagulation [1]. Thrombin generation from prothrombin may be measured by the appearance in the blood of prothrombin fragments 1 & 2 (F1+2). A first human dose (FHD) trial investigated the safety and the PK of NN1731, including measurements of F1+2 in plasma. It was attempted to investigate the feasibility of establishing a population PK/PD model of NN1731 pharmacologic effect to enable a future estimation of a relative potency of NN1731 compared to native recombinant FVIIa (rFVIIa, NovoSeven®).. Methods: The FHD trial was a dose escalation trial with 4 cohorts of patients (5, 10, 20 and ...
Supplementary MaterialsS1 Methods: Detailed explanation of prekallikrein production and prothrombin/factor X lacking plasma assays. Aliquots of 10 L PD184352 ic50 had been taken and generated kallikrein enzymatic activity was determined using the specific chromogenic substrate S2302 (2 mM). The kinetics of p-nitroaniline formation were monitored at 405 nm and curves are representative data from at least three independent experiments. Inset shows the dose-response curve. The amounts of plasma derived kallikrein generated by LOBE was estimated using a calibration curve made with known concentrations of purified kallikrein and thus expressed as pmol of equivalent kallikrein/mL/min.(TIF) pntd.0007197.s004.tif (459K) GUID:?7403B6A2-C7C2-4032-B696-330A483F7AED S4 Fig: LOBE-induced kallikrein generation in factor X and prothrombin deficient PD184352 ic50 plasma. To further confirm LOBE-induced kallikrein activation specificity, the main procoagulant factors, FX and prothrombin (PThr), were depleted ...
factor Xa inhibitor treatment of deep vein thrombosis knee hip replacement surgery rivaroxaban Xarelto act up on prothrombin and convert prothrombin to thrombin
Proteinase K Solution, 600 mAU/ml Efficient removal of proteins from nucleic acid solutions - Find MSDS or SDS, a COA, data sheets and more information.
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
Thrombin is a serine protease that in humans is encoded by the F2 gene. Prothrombin (coagulation factor II) is proteolytically cleaved to form thrombin in the coagulation
Coagulation is a complex process to form clots of platelets and fibrin to stop bleeding. After damage of a blood vessel a cascade of signals is initiated (extrinsic), starting with Factor (F) VII to activate FIX and FX and its cofactor FVa to release thrombin from prothrombin (FII), which allows to convert fibrinogen to fibrin and to crosslink it (through FXIII), but also activates FV, FVIII and their inhibitor protein C (compressed summary). Increased risk of bleeding and increased clotting (thrombosis) are well-known disorders of coagulation. There are several mutations in these genes known, having an influence on the coagulation. Most prominent is the FV variant R506Q, causing APC resistance and increasing the risk for thrombosis. Also well-known is the prothrombin (F2) G20210A mutation, increasing the risk for blood clots in the deep veins. ...
Eating foods that have vitamin K, such as broccoli, chickpeas, kale, turnip greens, and soybean products.Wrap an elastic band around your upper arm to stop the flow of blood.It may be ordered along with a prothrombin time (PT) test to evaluate.Sixty whole blood samples were collected into. tests (e.g., PT and PTT).INR (international normalized ratio) stands for a way of standardizing the results of prothrombin time tests, no matter the testing method.Reasons you may not be able to have the test or why the results may not be helpful include.You may feel nothing at all from the needle, or you may feel a quick sting or pinch.. The combination of both tests examines how the factors work together, and evaluation of both results together can help diagnose certain conditions.The PT and PTT Blood Tests are useful in the diagnosis of excessive, unexplained bleeding in patients who are not taking blood-thinning medications.A PTT test is commonly performed in conjunction with another clothing test called ...
A prothrombin time test measures how long it takes for your blood plasma to clot. Prothrombin, or factor II, is one of 12 proteins in the clotting process ...
Doctors may order a PT test as part of an evaluation for a bleeding disorder or to monitor the effects of blood-thinning medicine.
This test is one of several that looks at how well your blood clots. Your doctor may use this test to help diagnose a blood clotting disorder.
COAGULANTE Chinfield covers all the hemorrhage conditions, of any etiology and localization, thanks to its two formulation active ingredients, which distinguish them as a unique product in its group. Administered when a blood effusion occurs, it immediately obtains the complete stop of hematic effusion, and if administered as a means of prevention, blood loss is avoided. Injected one hour before any surgery, a clearer surgical field will be obtained and thus, the surgical maneuver is facilitated. Vitamin K, due to its involvement in prothrombin formation, and the Cyclonamine, by accelerating the transformation of prothrombin into thrombin, significantly prolongs the products uptime.. ...
Seegers WH, Johnson JF, Fell C (1954). "An antithrombin reaction to prothrombin activation". Am. J. Physiol. 176 (1): 97-103. ...
Anticoagulants: Coadministration may prolong prothrombin time. Aspirin: Fenoprofen Cl may be increased; coadministration is not ...
Prothrombin G20210A defect. altered coagulation. [14] Hyperhomocysteinemia. altered coagulation. [14] Elevated factors II, VIII ...
Prothrombin G20210A[4]. *Dysfibrinogenemia[6]. *Non O-blood type[17]. Mixed[edit]. *Low free protein S[13] ...
Prothrombin level abnormal. *bulbous skin reaction[20]. Rare (0.01-0.1% frequency) *QT interval prolongation[Note 36] ...
Prothrombin was discovered by Pekelharing in 1894. Thrombin is produced by the enzymatic cleavage of two sites on prothrombin ... Prothrombin G20210A is congenital. Prothrombin G20210A is not usually accompanied by other factor mutations (i.e., the most ... Prothrombin complex concentrate and fresh frozen plasma are prothrombin-rich coagulation factor preparations that can be used ... Activation of prothrombin is crucial in physiological and pathological coagulation. Various rare diseases involving prothrombin ...
As a result, TBA prolongs the prothrombin time when interacting with prothrombin. TBA entered the phase I clinical trial for ... Ecarin activates prothrombin and accordingly produces meizothrombin. The exosite II is not accessible in meizothrombin, so thus ... Furthermore, TBA recognizes and inhibits prothrombin with similar affinity against alpha-thrombin. ... binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. The Journal of Biological ...
In 1975, he published a classic paper on the biosynthesis of prothrombin. Kresge N, Simoni RD, Hill RL (May 2009). "The Finding ... Fernlund P, Stenflo J, Roepstorff P, Thomsen J (August 1975). "Vitamin K and the biosynthesis of prothrombin. V. Gamma- ... carboxyglutamic acids, the vitamin K-dependent structures in prothrombin". J. Biol. Chem. 250 (15): 6125-33. PMID 50323. v t e ... That Prothrombin Contains γ-Carboxyglutamic Acid: the Work of Johan Stenflo". Journal of Biological Chemistry. 284 (18): e1. " ...
... reacts with prothrombin in the blood. The resulting complex is called staphylothrombin, which enables the enzyme to ...
Prothrombin fragment 1+2. Increases. No change Activated protein C resistance. Increases. No change ...
Blood tests: Prothrombin time Partial thromboplastin time "hemostasis". Merriam-Webster Dictionary. Retrieved 2016-01-21. " ...
Bleeding in an infant without vitamin K supplementation with elevated prothrombin time (PT) that is corrected by vitamin K ... Severe bleeding may require blood products such as fresh frozen plasma (FFP), a prothrombin complex concentrate (PCC). Sutor, ... administration which restores the prothrombin time rapidly. ...
Prothrombinases turn prothrombins to thrombins. Thrombins turn blood-soluble fibrinogens to insoluble fibrins, which are the ...
Prothrombin is a coagulation factor critical in the initial steps of blood clotting. They prepared the human prothrombin from ... Several years later, after isolating cDNA for prothrombin from mice, they were able to characterize the complete prothrombin ... Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events ... Prothrombin deficiency results in embryonic and neonatal lethality in mice Proceedings of the National Academy of Sciences of ...
This can lead to an increase in prothrombin time. Zileuton is an active oral inhibitor of the enzyme 5-lipoxygenase, which ... although significant increase in prothrombin time is not obvious. It is advised that the doses of each medication be monitored ...
In liver disease, prothrombin time is longer than usual. In addition, the amounts of both coagulation factors and ... serum proteins, serum albumin, serum globulin, alanine transaminase, aspartate transaminase, prothrombin time, partial ...
Two years later, the same group described a common mutation in the prothrombin gene that caused elevation of prothrombin levels ... untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous ... The prothrombin mutation occurs at rates of 1-4% in the general population, 5-10% of people with thrombosis, and 15% of people ... The most common ones are factor V Leiden (a mutation in the F5 gene at position 1691) and prothrombin G20210A, a mutation in ...
"Livedo Vasculopathy Associated with IgM Anti-phosphatidylserine-prothrombin Complex Antibody". Acta Dermato Venereologica. 90 ( ... in a patient with sarcoidosis and Sjögren's syndrome Livedo vasculopathy associated with IgM antiphosphatidylserine-prothrombin ... complex antibody Livedo vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity and prothrombin ...
Prothrombin time (PT) and its derived measures of prothrombin ratio (PR) and INR are measures of the extrinsic pathway of ... "Prothrombin Time Test and INR (PT/INR): MedlinePlus Medical Test". medlineplus.gov. Retrieved 25 February 2021. "How Often ... These tests include prothrombin time (PT/INR), activated Partial Thromboplastin Time (aPTT), albumin, bilirubin (direct and ...
These same herbal supplements taken with warfarin increased prothrombin time. By containing significant content of vitamin K, ...
It is recommended that the effects of warfarin typically be monitored by checking prothrombin time (INR) every one to four ... Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, Crowther M (October 2016). "Prothrombin complex ... The effects of warfarin may be reversed with phytomenadione (vitamin K1), fresh frozen plasma, or prothrombin complex ... prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP). Generally, 4-factor PCC can be given more quickly than FFP ...
Prolonged prothrombin time can be caused by vitamin K deficiency. Serological studies. Specific tests are carried out to ...
The risk of bleeding may be increased if: prothrombin time > 21 seconds international normalized ratio > 1.6 platelet count < ...
An increase in prothrombin time, a coagulation assay, has been used as an indicator of vitamin K status, but it lacks ... ISBN 978-1-118-06572-3. Rao VS, Joseph JS, Kini RM (February 2003). "Group D prothrombin activators from snake venom are ... which has the functional consequence of increasing prothrombin time - a measure of blood clotting activity - and in severe ... "Vitamin K dependent modifications of glutamic acid residues in prothrombin". Proceedings of the National Academy of Sciences of ...
... essentially decreasing prothrombin production. This is associated with bleeding from birth. Here, plasma levels of prothrombin ... Prothrombin is a glycoprotein that occurs in blood plasma and functions as a precursor to the enzyme, thrombin, which acts to ... Prothrombin blood test: Determines if patient has deficient or low levels of Factor II. Vitamin K1 test: Performed to evaluate ... Prothrombin is a critical protein that is involved in the process of hemostasis, as well as illustrating procoagulant ...
Important negative prognostic indicators include ascites, encephalopathy, elevated Child-Pugh scores, elevated prothrombin time ... "Prothrombin Mutation G20210A as a Cause of Budd-Chiari Syndrome" (PDF). Hospital Physician. 39 (8): 41-4. Archived from the ... hereditary anti-thrombin deficiency and prothrombin mutation G20210A. An important non-genetic risk factor is the use of ...
... is a state of high of prothrombin levels in the blood which leads to hypercoagulability. An example of a ... genetic cause includes the mutation prothrombin G20210A. Blood coagulation Hyperprothrombinemia Merriam Webster Dictionary. ...
... "p38 MAPK controls prothrombin expression by regulated RNA 3′ end processing". Molecular Cell. 41 (3): 298-310. doi:10.1016/j. ...
A specific FX concentrate was not available as of 2009[update]. Prothrombin complex concentrate (PCC) supplies FX with a risk ... Veneri D, Giuffrida AC, Bonalumi A, Calabria S, Gandini G, Ambrosetti A, Minuz P (November 2016). "Use of prothrombin complex ... Produced in the liver FX when activated cleaves prothrombin to generate thrombin in the intrinsic pathway of coagulation. This ... Typical are normal thrombin time, prolonged prothrombin time (PT) and prolonged partial thromboplastin time(PTT). FX antigen ...
Prothrombin complex concentrates are preferred for severe bleeding. Recombinant factor VIIa is reserved for life-threatening ... For those who were under warfarin treatment, fresh frozen plasma (FFP), vitamin K, prothrombin complex concentrates, or ...
Measurement of an elevated plasma prothrombin level cannot be used to screen for the prothrombin G20210A mutation, because ... "Prothrombin Gene Mutation , Fact Sheets". www.melbournehaematology.com.au. Retrieved 2016-05-06.. [better source needed] ... Because prothrombin is also known as factor II, the mutation is also sometimes referred to as the factor II mutation or simply ... untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous ...
Prothrombin thrombophilia is an inherited disorder of blood clotting. Explore symptoms, inheritance, genetics of this condition ... The particular mutation that causes prothrombin thrombophilia results in an overactive F2 gene that causes too much prothrombin ... Prothrombin thrombophilia is caused by a particular mutation in the F2 gene. The F2 gene plays a critical role in the formation ... People who have prothrombin thrombophilia are at somewhat higher than average risk for a type of clot called a deep venous ...
The prothrombin time ratio is the ratio of a subjects measured prothrombin time (in seconds) to the normal laboratory ... Indeed, a new prothrombin time variant, the Fiix prothrombin time, intended solely for monitoring warfarin and other vitamin K ... The prothrombin time (PT) - along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR ... The Fiix prothrombin time is only affected by reductions in factor II and/or factor X and this stabilizes the anticoagulant ...
Prothrombin activator is a complex of a dozen blood coagulation factors that functions in catalyzing prothrombin into thrombin ... Prothrombin activator is released in the body by a cascade of chemical reactions in response to damage in a blood vessel. ...
What Is a Prothrombin Time Test?. A prothrombin time (PT) test measures how long it takes for a clot to form in a blood sample ...
the prothrombin time (pt) test measures how long it takes your blood to clot. if it takes a long time, that could be a sign of ... What is a prothrombin time test?. ANSWER The prothrombin time (PT) test measures how long it takes your blood to clot. If it ...
... ,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory ... Factor V/Prothrombin ASRs*. 2. Factor II,Activity (Prothrombin). 3. Prothrombin (Factor II). 4. Prothrombin Nucleotide 20210 G/ ... Prothrombin Antibody, IgM. 6. Prothrombin Nucleotide 20210 G/A Gene Mutation (Factor II), Fetal. 7. Prothrombin Time. 8. ... Prothrombin Timewith Reflex to PT 1:1 Mix. 9. Prothrombin Time/International Normalized Ratio. 10. Adenovirus Antibody, IgG. 11 ...
... the time required for a particular specimen of prothrombin to induce blood-plasma clotting under standardized conditions in ... Share prothrombin time Post the Definition of prothrombin time to Facebook Share the Definition of prothrombin time on Twitter ... Dictionary Entries near prothrombin time. prothrombase prothrombin prothrombinopenia prothrombin time protide protirelin ... Comments on prothrombin time What made you want to look up prothrombin time? Please tell us where you read or heard it ( ...
prothrombin synonyms, prothrombin pronunciation, prothrombin translation, English dictionary definition of prothrombin. n. A ... Related to prothrombin: prothrombin factor, Prothrombin complex concentrate, Prothrombin ratio, Prothrombin complex ... Prothrombin - definition of prothrombin by The Free Dictionary https://www.thefreedictionary.com/prothrombin ... prothrombin. (prəʊˈθrɒmbɪn) n. (Biochemistry) biochem a zymogen found in blood that gives rise to thrombin on activation. See ...
... Polymerase chain reaction (PCR) DNA extraction Molecular Genetics. ... The F2 gene encodes coagulation Factor II, also known as prothrombin, protein. The presence of 20210G,A mutation in the F2 gene ... that manifest most commonly in adults and is associated with elevated prothrombin levels. ... increases the patients risk for prothrombin-related thrombophilia, which is characterized by venous thromboembolism (VTE) ...
... , ProTime, Pro-Time, PT, International Normalized Ratio, INR. ... Prothrombin Time, Prothrombin Times, Time, Prothrombin, Times, Prothrombin, One stage prothrombin time, PROTHROMBIN TIME, ... Prothrombin Time Test, PTT - Prothrombin time, prothrombin time (PT) (lab test), prothrombin time (PT), prothrombin time, Pro- ... thrombin time, prothrombin times, Test;prothrombin time, Prothrombin time assay, prothrombin test, prothrombin time (PT) test, ...
Prothrombin test definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it ... Words nearby prothrombin test. prothoracic gland, prothorax, prothrombin, prothrombin accelerator, prothrombinase, prothrombin ... A method for determining prothrombin concentrations in blood based on the clotting time of oxalated blood plasma in the ...
A prothrombin time test tells you how long it takes your blood to clot. Learn what it looks for, when you might need one, and ... University of Rochester Medical School: "Prothrombin Time.". Lab Tests Online: "Prothrombin Time and International Normalized ... Thats when you might need a prothrombin time test, which measures how quickly your blood clots. Its also called a PT, pro ... KidsHealth: "Blood Test: Prothrombin Time," "Blood Test: Partial Thromboplastin Time (PTT).". ...
Prothrombin, or factor II, is one of 12 proteins in the clotting process. ... A prothrombin time test measures how long it takes for your blood plasma to clot. ... A prothrombin time (PT) test measures the amount of time it takes for your blood plasma to clot. Prothrombin, also known as ... Why is a prothrombin time test performed?. When you get a cut and your blood vessel ruptures, blood platelets collect at the ...
I was diagnosed with this, my parents went to be tested today and my mum said she was told that it didnt have to have come from one of my parents. She couldnt...
Prothrombin-Time Self Testing Coalition McDermott, Will & Emery. THIRD QUARTER (NO ACTIVITY). $0. ... Prothrombin-Time Self Testing Coalition McDermott, Will & Emery. FOURTH QUARTER (NO ACTIVITY). $0. ... Prothrombin-Time Self Testing Coalition McDermott, Will & Emery. FIRST QUARTER REPORT. $10,000. ... Prothrombin-Time Self Testing Coalition McDermott, Will & Emery. SECOND QUARTER REPORT. $10,000. ...
Explore the billions of dollars special interest groups are spending on lobbying in Washington, D.C., -- and on what -- at OpenSecrets.org.
Prothrombin time is the number of seconds it takes for the blood plasma to... ... A normal prothrombin time is 11 to 13.5 seconds for patients who are not taking anticoagulants, according to MedlinePlus. ... Prothrombin time is the number of seconds it takes for the blood plasma to clot. An elevated prothrombin time means the blood ... Prothrombin time tests may also be ordered to look for causes of abnormal bruising or bleeding, check liver function or look ...
Prothrombin time is a measure of blood clotting function. More than likely, the changes from normal to abnormal and back to ... Prothrombin. Feb 2, 2002 Dr. I had prothrombin checked at 1 dr who said it was elevated as shown in lab work . Then i had it ... Prothrombin time is a measure of blood clotting function. More than likely, the changes from normal to abnormal and back to ... Could this be caused by not handling the blood properly or does prothrombin tend to fluctuate. If it does how do I know if it ...
Detailed drug Information for prothrombin complex human Intravenous. Includes common brand names, drug descriptions, warnings, ... Prothrombin complex human contains coagulation factors II, VII, IX, and X, and proteins C and S. Prothrombin complex human is ... Proper Use of prothrombin complex human. A doctor or other trained health professional will give you prothrombin complex human ... Uses For prothrombin complex human. Prothrombin complex concentrate human injection is used to reverse the effects of ...
Prothrombin. P00734. Details. Drug Relations. Drug Relations. DrugBank ID. Name. Drug group. Pharmacological action?. Actions. ... Prothrombin. Kind. protein. Organism. Humans. Polypeptides. Name. UniProt ID. ...
SEARCH RESULTS for: Increased Prothrombin Activity [Drug Class] (34 results) * Share : JavaScript needed for Sharing tools. ...
... What It Is. A prothrombin time (PT) test measures how long it takes for a clot to form in a ... Prothrombin time is also useful in monitoring the effects of the blood-thinning medication warfarin. Blood thinners are ... Prothrombin time is measured in seconds. The results are compared with the average clotting time of healthy people. ...
What Is a Prothrombin Time Test?. A prothrombin time (PT) test measures how long it takes for a clot to form in a blood sample ... Blood Test: Prothrombin Time (PT). Article Translations: (Spanish). What Is a Blood Test?. A blood test is when a sample of ...
Anti-Prothrombin antibody conjugated to Biotin validated for WB, IP, RIA, cELISA and tested in Human. Immunogen corresponding ... Note=A common genetic variation in the 3-prime untranslated region of the prothrombin gene is associated with elevated plasma ... which is essential for the conversion of prothrombin to thrombin. ... Anti-Prothrombin antibody (Biotin). See all Prothrombin primary ...
A one-stage prothrombin assay which measures the exponential rate of thrombin production in thromboplastin-treated, recalcified ... The one-stage prothrombin times are represented by t and t for the two plasmas. As discussed above, typical prothrombin times ... The lengthened prothrombin time of the abnormal plasma is evidenced by the lowered slope of the curve. Using the expression eat ... Moreover, the prothrombin time measurement of the prior art does not lend itself very well to automation, which is a highly ...
Find information on Prothrombin Complex Concentrate (Human) - Kcentra in Daviss Drug Guide including dosage, side effects, ... prothrombin complex concentrate (human) is a sample topic from the Daviss Drug Guide. To view other topics, please log in or ... "Prothrombin Complex Concentrate (human)." Daviss Drug Guide, 16th ed., F.A. Davis Company, 2020. Washington Manual, www. ... Prothrombin Complex Concentrate (human) [Internet]. In: Daviss Drug Guide. F.A. Davis Company; 2020. [cited 2021 July 28]. ...
I also found out I have Factor V Leiden and Prothrombin Gene Mutation G20210. So does this mean Coumadin for life??? Also,... ... I also found out I have Factor V Leiden and Prothrombin Gene Mutation G20210. So does this mean Coumadin for life???. Also, ...
Buy our Natural Human Prothrombin protein. Ab62502 is a protein fragment produced in Nativesyntheticaly and has been validated ... Note=A common genetic variation in the 3-prime untranslated region of the prothrombin gene is associated with elevated plasma ... which is essential for the conversion of prothrombin to thrombin. ... Natural Human Prothrombin protein. See all Prothrombin proteins ...
Question: prothrombin gene mutation. doubtful - Mon Sep 21, 2009 6:12 pm. Share , ... A work up done to rule out cancer was negative however blood work showed a prothrombin gene mutation. At the time I was taking ...
  • Coagulation studies at that time showed a prolonged prothrombin time of 18 seconds {normal 11. (thefreedictionary.com)
  • A 47-year-old African American woman was evaluated for a prolonged prothrombin time (PT) result obtained before she underwent right total hip arthroplasty. (aacc.org)
  • Prolonged prothrombin time (PT) is a laboratory blood test result showing that blood clots too slowly which makes the patient subject to abnormal bleeding. (glutenfreeworks.com)
  • [5] Prothrombin is the precursor to thrombin , which plays a key role in causing blood to clot ( blood coagulation ). (wikipedia.org)
  • The protein produced from the F2 gene, prothrombin (also called coagulation factor II), is the precursor to a protein called thrombin that initiates a series of chemical reactions in order to form a blood clot. (medlineplus.gov)
  • The prothrombin time (PT) - along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) - are assays evaluating the extrinsic pathway and common pathway of coagulation. (wikipedia.org)
  • PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X (Stuart-Prower factor). (wikipedia.org)
  • Prothrombin activator is a complex of a dozen blood coagulation factors that functions in catalyzing prothrombin into thrombin. (wikipedia.org)
  • The F2 gene encodes coagulation Factor II, also known as prothrombin, protein. (nationwidechildrens.org)
  • Prothrombin complex human contains coagulation factors II, VII, IX, and X, and proteins C and S. Prothrombin complex human is used to stop bleeding by helping the blood to clot. (drugs.com)
  • 13 Hypothetically, prothrombin complex concentrate (PCC) could overcome the anticoagulant effect induced by thrombin and factor Xa inhibitors because PCC contains the coagulation factors II, VII, IX, and X in a high concentration and in general enhances thrombin generation. (ahajournals.org)
  • In contrast to blood coagulation factors that circulate as inactive zymogen in plasma, venom prothrombin activators are always found in the active form in the venom. (uniprot.org)
  • 1. the activated form of coagulation factor II (prothrombin), which catalyzes the conversion of fibrinogen to fibrin. (thefreedictionary.com)
  • the key enzyme produced during coagulation by activation of prothrombin. (thefreedictionary.com)
  • Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K (2003) Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. (springer.com)
  • Prothrombin complex concentrate provides an increase in the levels of the vitamin K-dependent coagulation factors (II, VII, IX, and X) with the addition of protein C and protein S. Coagulation factors II, IX, and X are part of the intrinsic coagulation pathway, while factor VII is part of the extrinsic coagulation pathway. (drugs.com)
  • Prothrombin complex concentrates (PCC) are currently used to treat congenital or acquired coagulation factor deficiency. (springermedizin.at)
  • Prothrombin G20210A is a genetic condition that increases the risk of blood clots including deep vein thrombosis and pulmonary embolism . (wikipedia.org)
  • Prothrombin G20210A was identified in the 1990s. (wikipedia.org)
  • [2] Behind non-O blood type [7] and factor V Leiden , prothrombin G20210A is one of the most common genetic risk factors for VTE. (wikipedia.org)
  • Diagnosis of the prothrombin G20210A mutation is straightforward because the mutation involves a single base change (point mutation) that can be detected by genetic testing, which is unaffected by intercurrent illness or anticoagulant use. (wikipedia.org)
  • Measurement of an elevated plasma prothrombin level cannot be used to screen for the prothrombin G20210A mutation, because there is too great of an overlap between the upper limit of normal and levels in affected patients. (wikipedia.org)
  • Patients with the prothrombin G20210A mutation who have not had a thromboembolic event are generally not treated with routine anticoagulation. (wikipedia.org)
  • Clinical and laboratory management of the prothrombin G20210A mutation. (medlineplus.gov)
  • However, the patient was found to have a heterozygous prothrombin G20210A (factor II) mutation. (thefreedictionary.com)
  • Prothrombin (Factor II) G20210A mutation is associated with elevated prothrombin levels. (uhhospitals.org)
  • Analysis for the prothrombin G20210A mutation is offered as a specific DNA test, or as part of a thrombophilia panel (see Thrombosis panel) which also includes the factor V Leiden analysis. (uhhospitals.org)
  • Prothrombin G20210A mutation and lower extremity peripheral arterial disease: a systematic review and meta-analysis. (nih.gov)
  • Despite being an important risk factor for venous thromboembolism, the role of the prothrombin G20210A mutation in patients with arterial disease remains unclear. (nih.gov)
  • The aim of this review was to evaluate the association of prothrombin G20210A and lower extremity peripheral arterial disease (PAD). (nih.gov)
  • A systematic review of electronic databases, including MEDLINE and Embase, was conducted to assess the prevalence of prothrombin G20210A in patients with lower extremity PAD. (nih.gov)
  • The main outcome was the prevalence of prothrombin G20210A in patients with lower extremity PAD. (nih.gov)
  • Prothrombin G20210A was found in 70 of 1,524 patients with lower extremity PAD and 44 of 1,553 of the controls (random effects OR 1.68, 95% confidence interval [CI] 0.8-3.2). (nih.gov)
  • In those with critical limb ischemia (CLI), the prevalence of prothrombin G20210A was 23 of 302 compared with 31 of 1,253 of the controls (OR 3.2, 95% CI 1.6-6.1). (nih.gov)
  • Despite finding no significant association between lower extremity PAD and prothrombin G20210A, the meta-analysis suggests that the prevalence of prothrombin G20210A is significantly elevated in those with atherosclerotic occlusive disease of the lower extremities presenting with CLI. (nih.gov)
  • Well-designed prospective cohort studies evaluating the role of prothrombin G20210A as a predictor of disease progression or adverse vascular events are highly needed. (nih.gov)
  • Objective- Individuals with elevated prothrombin, including those with the prothrombin G20210A mutation, have increased risk of venous thrombosis. (ahajournals.org)
  • Background -G20210A prothrombin mutation has been associated with high prothrombin levels and an increased risk of venous thrombosis. (ahajournals.org)
  • Methods and Results -We determined the prevalence of the G20210A mutation and prothrombin activity in 660 individuals, of whom 436 had angiographically documented severe coronary artery disease (CAD patients) and 224 had normal coronary angiography (CAD-free control subjects). (ahajournals.org)
  • Conclusions -In a population with a clear-cut definition of the phenotype, the G20210A prothrombin mutation was not significantly associated, per se, with either angiographically documented CAD or myocardial infarction, whereas it significantly influenced prothrombin activity. (ahajournals.org)
  • We examined the prevalence of the G20210A prothrombin mutation in a population of subjects with angiographic documentation of the condition of their coronary vessels. (ahajournals.org)
  • It is due to a specific gene mutation in which a guanine (G) is changed to an adenine (A) at position 20210 of the DNA of the prothrombin gene. (wikipedia.org)
  • Patients with the prothrombin mutation are treated similarly to those with other types of thrombophilia, with anticoagulation for at least three to six months. (wikipedia.org)
  • Prothrombin thrombophilia is caused by a particular mutation in the F2 gene. (medlineplus.gov)
  • The particular mutation that causes prothrombin thrombophilia results in an overactive F2 gene that causes too much prothrombin to be produced. (medlineplus.gov)
  • The risk of developing an abnormal clot in a blood vessel depends on whether a person inherits one or two copies of the F2 gene mutation that causes prothrombin thrombophilia. (medlineplus.gov)
  • Prothrombin 20210 mutation (factor II mutation). (medlineplus.gov)
  • Objective: To determine the frequency of prothrombin gene mutation in venous thromboembolism in our population. (thefreedictionary.com)
  • A mutation in the F2 gene increases the patient's risk for prothrombin-related thrombophilia, which is characterized by venous thromboembolism (VTE) that manifest most commonly in adults and is associated with elevated prothrombin levels. (nationwidechildrens.org)
  • I also found out I have Factor V Leiden and Prothrombin Gene Mutation G20210. (dailystrength.org)
  • A work up done to rule out cancer was negative however blood work showed a prothrombin gene mutation. (doctorslounge.com)
  • Can prothrombin genetic mutation be inherited? (healthtap.com)
  • however, the patient was found to be heterozygous for the 20210A prothrombin gene mutation. (bmj.com)
  • A mutation in the prothrombin gene (G→A 20210 ) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis. (annals.org)
  • The polymorphism is located in a noncoding region of the prothrombin gene ( 3' untranslated region nucleotide 20210 [b] ), replacing guanine with adenine . (wikipedia.org)
  • It is known that mutations in the prothrombin gene are a risk factor for thrombosis. (thefreedictionary.com)
  • Note=A common genetic variation in the 3-prime untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased risk of venous thrombosis. (abcam.com)
  • 2 3 Among these, a recently examined potential candidate is the prothrombin gene. (ahajournals.org)
  • In 1996, Poort et al 5 described a variant of the prothrombin gene (ie, a G to A substitution at position 20210 in the 3′-untranslated region) that was associated with higher prothrombin levels and with an increased risk of venous thrombosis. (ahajournals.org)
  • Recently, a single nucleotide substitution (G to A) at position 20210 in the 3' untranslated region of the gene encoding prothrombin has been identified. (bmj.com)
  • This was identified using the polymerase chain reaction (PCR) of exon 14 and the 3'-untranslated region of the prothrombin gene, followed by restriction digestion by Hind III. (bmj.com)
  • The structure of bovine prothrombin fragment 1 has been refined at 2.25 A resolution using high resolution measurements made with the synchrotron beam at CHESS. (rcsb.org)
  • an enzyme resulting from activation of prothrombin, which catalyzes the conversion of fibrinogen to fibrin. (thefreedictionary.com)
  • Factor Xa activates prothrombin (factor II) into thrombin (IIa) which converts fibrinogen into fibrin resulting in clot formation. (drugs.com)
  • A prothrombin time (PT) test measures how long it takes for a clot to form in a blood sample. (kidshealth.org)
  • The prothrombin time (PT) test measures how long it takes your blood to clot. (webmd.com)
  • INR = ( PT test PT normal ) ISI {\displaystyle {\text{INR}}=\left({\frac {{\text{PT}}_{\text{test}}}{{\text{PT}}_{\text{normal}}}}\right)^{\text{ISI}}} The prothrombin time is the time it takes plasma to clot after addition of tissue factor (obtained from animals such as rabbits, or recombinant tissue factor, or from brains of autopsy patients). (wikipedia.org)
  • A prothrombin time (PT) test measures the amount of time it takes for your blood plasma to clot. (healthline.com)
  • Prothrombin time is the number of seconds it takes for the blood plasma to clot. (reference.com)
  • Pro time is the shortened name of the prothrombin time test, which measures how long it takes the plasma to clot, explains MedlinePlus. (reference.com)
  • See also blood clot , prothrombin . (thefreedictionary.com)
  • The Prothrombin Time (PT/INR) and Partial Thromboplastin time (PTT) test is used to measure the duration needed for your blood to clot. (healthtestingcenters.com)
  • It activates prothrombin (FII) to thrombin, the principal stimulator of clot formation in vivo. (queensu.ca)
  • Anonactivated, 4-factor prothrombin complex concentrate (4F-PCC) known as Kcentra (CSL Behring, Kankakee, Illinois) has been approved in the United States for the reversal of vitamin K antagonist (VKA) anticoagulation in patients with major acute hemorrhage, or in patients who require urgent surgical intervention. (thefreedictionary.com)
  • Monitor patients receiving prothrombin complex concentrate (human) for signs and symptoms of TE. (drugs.com)
  • Prothrombin complex concentrate human injection is used to reverse the effects of anticoagulants or blood thinners (eg, warfarin, Coumadin®, Jantoven®) in adult patients with acute major bleeding. (drugs.com)
  • Prothrombin complex human is to be given only by or under the supervision of your doctor. (drugs.com)
  • Tell your doctor if you have ever had any unusual or allergic reaction to prothrombin complex human or any other medicines. (drugs.com)
  • Appropriate studies have not been performed on the relationship of age to the effects of prothrombin complex concentrate human injection in the pediatric population. (drugs.com)
  • Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of prothrombin complex concentrate human injection in the elderly. (drugs.com)
  • When you are receiving prothrombin complex human, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. (drugs.com)
  • Using prothrombin complex human with any of the following medicines is usually not recommended, but may be required in some cases. (drugs.com)
  • The presence of other medical problems may affect the use of prothrombin complex human. (drugs.com)
  • Administer Vitamin K concurrently to maintain Vitamin K-dependent clotting factor levels once effects of prothrombin complex concentrate human have diminished. (unboundmedicine.com)
  • Inform patient of purpose of prothrombin complex concentrate human. (unboundmedicine.com)
  • This study evaluated the potential of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of these drugs. (ahajournals.org)
  • Conclusion- Prothrombin complex concentrate immediately and completely reverses the anticoagulant effect of rivaroxaban in healthy subjects but has no influence on the anticoagulant action of dabigatran at the PCC dose used in this study. (ahajournals.org)
  • Future Investments In Global Human Prothrombin Complex Ma. (pharmiweb.com)
  • Global Human Prothrombin Complex Market Report provides main statistics connected to the overall market and value forecast over a period, from 2019 to 2028. (pharmiweb.com)
  • This research report studies human prothrombin complex market definition, types, applications latest trends to recognize the revenues and the progress of the market over the forecast period. (pharmiweb.com)
  • Further, the report depicts various human prothrombin complex market growth influential factors which comprise raw material sources, industry environment, rapidly increasing demand, and technological developments. (pharmiweb.com)
  • Worldwide Human Prothrombin Complex Market report studies pin-point analysis for ever-changing competitive dynamics with regard to the growth factors that drive or restrains market growth. (pharmiweb.com)
  • The human prothrombin complex Industry report is collated to comprehend the market scenarios and possibilities where it has a scope to grow Within the future. (pharmiweb.com)
  • Market Segment can be classified on the basis of the regional analysis also report takes care of an important evaluation of human prothrombin complex market section from 2019 to 2028. (pharmiweb.com)
  • Research study on Global Human Prothrombin Complex Market also discusses the opportunity areas for stakeholders. (pharmiweb.com)
  • The report will help you to understand how and whether or not the global human prothrombin complex market has become customer-centric. (pharmiweb.com)
  • It offers deep insights into customer needs and preferences for players to increase their brand value, better connect with their clients, and improve their sales in the global human prothrombin complex market. (pharmiweb.com)
  • The Human Prothrombin Complex market is characterized by the presence of small independent companies, and there is a negligible number of large-scale operators. (pharmiweb.com)
  • To present Global Human Prothrombin Complex Market insight over the globe. (pharmiweb.com)
  • To evaluate and forecast the Human Prothrombin Complex Market on the basis of different segments. (pharmiweb.com)
  • To serves market size and forecast up to 2028 for complete Human Prothrombin Complex Market related to major regions. (pharmiweb.com)
  • To provide extended study for all Human Prothrombin Complex Market regions mentioned in the report. (pharmiweb.com)
  • To outlines major Human Prothrombin Complex Market players regulating the industry together with their SWOT analysis and Human Prothrombin Complex Market policies. (pharmiweb.com)
  • Lastly, the human prothrombin complex report offers market size and estimates for the period from 2019 to 2028, keeping in mind the above-mentioned factors. (pharmiweb.com)
  • This report will be helpful for human prothrombin complex vendors, system integrators, and related business partners to understand key investment areas and define their strategies. (pharmiweb.com)
  • 4-Factor Prothrombin Complex Concentrate (4F-PCC) is the standard-of-care intervention in patients with major bleeding taking oral vitamin K antagonists. (springer.com)
  • Yasaka M, Sakata T, Minematsu K, Naritomi H (2002) Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. (springer.com)
  • Yasaka M, Sakata T, Naritomi H, Minematsu K (2005) Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. (springer.com)
  • van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF (2006) Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. (springer.com)
  • Junagade P, Grace R, Gover P (2007) Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. (springer.com)
  • Khorsand N, Veeger NJ, Muller M, Overdiek JW, Huisman W, van Hest RM, Meijer K (2011) Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. (springer.com)
  • Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K (2012) An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. (springer.com)
  • Wozniak M, Kruit A, Padmore R, Giulivi A, Bormanis J (2012) Prothrombin complex concentrate for the urgent reversal of warfarin. (springer.com)
  • Varga C, Al-Touri S, Papadoukakis S, Caplan S, Kahn S, Blostein M (2013) The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin. (springer.com)
  • Klein L, Peters J, Miner J, Gorlin J (2015) Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. (springer.com)
  • In the second series, the reversal effect of prothrombin complex concentrates (PCC) and activated PCC (aPCC) in edoxaban-spiked plasma was evaluated. (springer.com)
  • If you have an allergy to prothrombin complex, heparin, or any other part of this drug. (mskcc.org)
  • The fragment 2-thrombin complex is only the second cassette module-catalytic domain structure to be determined for a multidomain blood protein and only the third domain-domain interaction to be described among such proteins, the others being factor Xa without a Gla domain and Ca2+ prothrombin fragment 1 with a Gla domain and a kringle. (rcsb.org)
  • prothrombin complex concentrate is a topic covered in the Taber's Medical Dictionary . (tabers.com)
  • Taber's Online, www.tabers.com/tabersonline/view/Tabers-Dictionary/739699/all/prothrombin_complex_concentrate. (tabers.com)
  • This report studies the global Human Prothrombin Complex market status and forecast, categorizes the global Human Prothrombin Complex market size (value & volume) by manufacturers, type, application, and region. (reportsnreports.com)
  • Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. (reportsnreports.com)
  • The global average price of Human Prothrombin Complex is in the increasing trend, from 124 USD/Unit in 2013 to 137 USD/Unit in 2017. (reportsnreports.com)
  • Human Prothrombin Complex is widely used in Hemophilia B, Vitamin K Deficiency and other diseases. (reportsnreports.com)
  • The global Human Prothrombin Complex market is valued at 1000 million US$ in 2017 and will reach 2430 million US$ by the end of 2025, growing at a CAGR of 11.8% during 2018-2025. (reportsnreports.com)
  • Focuses on the key Human Prothrombin Complex manufacturers, to study the capacity, production, value, market share and development plans in future. (reportsnreports.com)
  • Clinical studies on the effect of prothrombin complex concentrate (PCC) are heterogeneous with respect to outcome of bleeding. (rug.nl)
  • Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. (springermedizin.at)
  • Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis. (springermedizin.at)
  • Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (springermedizin.at)
  • Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. (springermedizin.at)
  • Therefore initially the Prothrombin Activator complex is still capable of converting prothrombin into thrombin even with the inactive Factor V component but becomes much more efficient once the Factor V is activated. (healthhype.com)
  • Prothrombin complex concentrate (PCC) is a drug that contains a source of proteins involved in the human blood clotting process. (cochrane.org)
  • We could not identify any beneficial effects of prothrombin complex concentrate on death. (cochrane.org)
  • In the four included RCTs , use of prothrombin complex concentrate does not appear to reduce mortality or transfusion requirements but demonstrates the possibility of reversing vitamin K-induced coagulopathy without the need for transfusion of fresh frozen plasma. (cochrane.org)
  • Reversal therapy with prothrombin complex concentrate (PCC) is used increasingly and is recommended in the treatment of patients with bleeding complications undertaking surgical interventions, as well as patients at high risk of bleeding. (cochrane.org)
  • A small number of options have been proposed in the event of an overdose: activated charcoal whenever possible, dialysis and/or the use of prohemostatic agents such as prothrombin complex concentrates (PCC), activated prothrombin complex concentrates (FEIBA), and recombinant activated factor VII (rFVIIa). (haematologica.org)
  • Four-factor prothrombin complex concentrates (PCCs), which contain factor II, FVII, FIX, and FX, have shown the potential to reverse the anticoagulant effect of rivaroxaban in healthy volunteers. (nih.gov)
  • Karaca, M.A., Erbil, B. and Ozmen, M.M. (2014) Use and Effectiveness of Prothrombin Complex Concentrates vs Fresh Frozen Plasma in Gastrointestinal Hemorrhage Due to Warfarin Usage in the ED. The American Journal of Emergency Medicine, 32, 660-664. (scirp.org)
  • ABSTRACT: Objective: The objective of this study was to analyse the reversibility of the anticoagulant effect of warfarin by comparing prothrombin complex concentrate (PCC) versus frozen fresh plasma (FFP) in cardiology patients with serious warfarin intoxication. (scirp.org)
  • CSL Behring announced results of a Phase 3b study that showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K antagonist therapy (eg, warfarin ). (empr.com)
  • Purpose The change in turnaround time of 4-factor prothrombin complex concentrate (PCC) when managed by the pharmacy department compared to blood bank management was evaluated. (ovid.com)
  • Monoclonal antibodies and fragments thereof, with binding specificity for an epitope on the carboxy terminus of prothrombin activation peptide F1.2, which can be used in immunoassays to predict thrombosis by measuring the extent of activation of prothrombin. (freepatentsonline.com)
  • The metalloprotease caused direct activation of prothrombin which was inhibited by the addition of ethylenediaminetetraacetic acid. (asm.org)
  • A prothrombin time, or international normalized ratio, test measures the amount of time it takes for a patient's blood to begin clotting in a laboratory se. (reference.com)
  • INR (international normalized ratio) stands for a way of standardizing the results of prothrombin time tests, no matter the testing method. (healthwise.net)
  • A method of standardizing prothrombin time results, called the international normalized ratio (INR) system, has been developed so the results among labs using different test methods can be understood in the same way. (healthwise.net)
  • Over time, his prothrombin time (PT)4 international normalized ratio (INR) values were stable and checked regularly at an anticoagulation clinic. (aacc.org)
  • The results of the prothrombin time test may vary from lab to lab, so health care providers use a ratio called the INR (international normalized ratio) to be able to account for the differences. (privatemdlabs.com)
  • Dosage is controlled by periodic determinations of the prothrombin time (PT)/International Normalized Ratio (INR). (clinicaltrials.gov)
  • Prothrombin activator is released in the body by a cascade of chemical reactions in response to damage in a blood vessel. (wikipedia.org)
  • 3. Process as claimed in claim 1, wherein the Factor Xa is produced by treating plasma with a prothrombin activator, centrifuging, mixing the supernatant with a protein adsorbent, eluting the precipitate with a protein elution agent and mixing the eluate with a Factor X activator and optionally with a soluble calcium salt. (freepatentsonline.com)
  • 8. Reagent for the determination of prothrombin in biological material, comprising a thrombin substrate and a prothrombin activator, wherein the prothrombin activator is Factor Xa in a concentration of from 0.2 to 2.5% of the biological material. (freepatentsonline.com)
  • 9. Reactant as claimed in claim 8 wherein the prothrombin activator is human Factor Xa. (freepatentsonline.com)
  • Snake prothrombin activator that attacks the hemostatic system of prey. (uniprot.org)
  • Activated Factor X (Xa) + Factor V* + platelet phospholipids = Prothrombin Activator . (healthhype.com)
  • Prothrombin Activator works with calcium to convert prothrombin into thrombin . (healthhype.com)
  • Lopap, found in the bristles of Lonomia obliqua caterpillar, is the first exogenous prothrombin activator that shows serine protease-like activity, independent of prothrombinase components and unique lipocalin reported to interfere with hemostasis mechanisms. (scielo.br)
  • The affinities of the vitamin K-dependent propeptides for the gamma-carboxylase vary over 2 logs, with the propeptide of factor X having the highest affinity followed by the propeptides of factor VII, protein S, factor IX, protein C, and prothrombin [Stanley, T. B. (1999) J. Biol. (nih.gov)
  • The results indicate that on average 85% of the total factor X produced with the prothrombin propeptide was fully gamma-carboxylated, representing a substantial improvement over a system that employs the native factor X propeptide, with which on average only 32% of the protein is fully gamma-carboxylated. (nih.gov)
  • Our results do not rule out the possibility that the rate of prothrombin activation is also influenced by a weaker, calcium-independent, and less specific acidic lipid binding site on prothrombin, the occupancy of which results in conformational changes in this protein. (eurekamag.com)
  • Prothrombin is the precursor of the serine protease thrombin, a key enzyme acting as a procoagulant, through platelet activation and the generation of fibrin and factors Va, VIIIa, and XIIIa, and subsequently as an anticoagulant, by activating circulating protein C. 4 Therefore, regulation of thrombin activity is crucial for maintaining hemostatic balance. (ahajournals.org)
  • Prothrombin is a protein produced by the liver that aids in the blood clotting process . (requestatest.com)
  • Acquired activated protein C resistance associated with IgG antibodies against [[beta].sub.2]-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. (thefreelibrary.com)
  • The variant causes elevated plasma prothrombin levels ( hyperprothrombinemia ), [4] possibly due to increased pre-mRNA stability. (wikipedia.org)
  • Detection of Prothrombin Activation with a Two-Site Enzyme Immunoassay for the Fragment F1.2," Thromb. (freepatentsonline.com)
  • However, the folding of fragment 2 is different from that of prothrombin kringle 1 and other kringles: the second outer loop possesses a distorted two-turn helix, and the hairpin beta-turn of the second inner loop pivots at Val64 and Asp70 by 60 degrees. (rcsb.org)
  • The level of prothrombin fragment F1+2 measured by ELISA had a 6-fold increase with rLopap treatment (10 µg/kg) and was inversely proportional to BT in LMWH-treated animals. (scielo.br)
  • Prothrombin is a precursor of the serine protease thrombin and is a key enzyme in the process of haemostasis. (bmj.com)
  • Mice infused with prothrombin demonstrated increased tissue factor-triggered thrombin generation measured ex vivo, but did not have increased circulating prothrombotic biomarkers in the absence of vessel injury. (ahajournals.org)
  • After venous injury, elevated prothrombin increased thrombin generation and the fibrin accumulation rate and total amount of fibrin ≈3-fold, producing extended thrombi with increased mass. (ahajournals.org)
  • Conclusions- These findings reconcile previously discordant findings on thrombin generation in hyperprothrombinemic individuals measured ex vivo and in vitro, and show elevated prothrombin promotes venous, but not arterial, thrombosis in vivo. (ahajournals.org)
  • After receiving 4 days of rivaroxaban 20 mg twice daily to obtain supratherapeutic steady-state concentrations, volunteers were randomized to receive a single 50 IU kg(-1) bolus dose of four-factor PCC, three-factor PCC or saline 4 h after the morning dose of rivaroxaban on day 5, and the effects of these interventions on prothrombin time and thrombin generation were determined. (nih.gov)
  • In this retrospective study, we evaluated the clinical relevance of antibodies to phosphatidylserine/prothrombin (aPS/PT) in Chinese patients with APS. (degruyter.com)
  • The normal range for pro-time, also known as prothrombin time, is 11 to 13 seconds, according to WebMD. (reference.com)
  • The modified residues are necessary for the calcium-dependent interaction with a negatively charged phospholipid surface, which is essential for the conversion of prothrombin to thrombin. (abcam.com)
  • A novel process for the determination of prothrombin in biological material, by conversion of prothrombin into thrombin, enzymatic fission of a thrombin substrate and measurement of a fission product, the improvement comprising incubating the test solution with the addition of Factor Xa. (freepatentsonline.com)
  • Research variables were AST/ALT ratio, prothrombin time, platelet conunt, serum albumin and serum bilirubin. (thefreedictionary.com)
  • However, elevated prothrombin did not accelerate platelet accumulation, increase the fibrin accumulation rate, or shorten the vessel occlusion time after arterial injury. (ahajournals.org)
  • Bosler D, Mattson J, Crisan D. Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype. (medlineplus.gov)
  • A normal prothrombin time is 11 to 13.5 seconds for patients who are not taking anticoagulants, according to MedlinePlus. (reference.com)
  • Doctors usually order a prothrombin time test to monitor patients during treatment with warfarin, an anticoagulant, explains MedlinePlus. (reference.com)
  • Liver disease and low levels of vitamin K may cause patients who are not taking warfarin to have an elevated prothrombin time. (reference.com)
  • For patients who are taking blood-thinning drugs, such as warfarin, the normal level of PT/INR or prothrombin time expressed in international normalized ra. (reference.com)
  • you are referring to the Prothrombin Time 'INR' result, this applies to patients on anticoagulant therapy. (medhelp.org)
  • Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin. (clinicaltrials.gov)
  • This side effect report can indicate a possible existence of increased vulnerability to Beloc-zok 50 treatment in patients suffering from cardiac failure , resulting in Prothrombin Time Abnormal . (patientsville.com)
  • A study of the prothrombin time of patients bitten by Bothrops snakes, principally Bothrops atrox , the fer-de-lance, was undertaken for possible use as a guide to the severity of envenomation and the effectiveness of antivenin medication. (ajtmh.org)
  • Fourteen patients carried both the prothrombin G→A 20210 and factor V Leiden mutations. (annals.org)
  • The prothrombin A 20210 allele is independently associated with the occurrence of venous thrombosis, particularly in patients with a history of thrombosis of the lower extremities. (annals.org)
  • The combination of prothrombin thrombophilia and mutations in other genes involved in blood clotting can also influence risk. (medlineplus.gov)
  • The presence of prothrombin G→A 20210 and factor V Leiden mutations was determined by polymerase chain reaction. (annals.org)
  • What Is a Prothrombin Time Test? (kidshealth.org)
  • The reference range for prothrombin time depends on the analytical method used, but is usually around 12-13 seconds (results should always be interpreted using the reference range from the laboratory that performed the test), and the INR in absence of anticoagulation therapy is 0.8-1.2. (wikipedia.org)
  • That's when you might need a prothrombin time test, which measures how quickly your blood clots. (webmd.com)
  • What risks are associated with a prothrombin time test? (healthline.com)
  • A prothrombin time test can be used to check for bleeding problems. (healthwise.net)
  • Prothrombin time is an important test because it checks to see if five different blood clotting factors (factors I, II, V, VII, and X) are present. (healthwise.net)
  • The U.S. Food and Drug Administration (FDA) has approved a home test for prothrombin time (PT). (healthwise.net)
  • The prothrombin time test measures how quickly prothrombin changes to thrombin to stop the bleeding. (ahealthyme.com)
  • The prothrombin time test may also be done if you have abnormal bleeding or clotting. (privatemdlabs.com)
  • Q: What does the prothrombin time (PT) test measure? (glutenfreeworks.com)
  • Tripodi A. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. (springer.com)
  • This direct access to physician offices as well as to hospitals and laboratories will be especially beneficial when it comes time to educate the point of care marketplace on the cardiac products we have under development, such as the prothrombin test due out in the US marketplace in 2006. (thefreedictionary.com)
  • The Health Department investigation showed that an incorrect laboratory formula number was used -- causing an error in the calculation of the Prothrombin Test (often referred to as a Protime Test or PT, which checks the rate at which blood is clotting). (thefreedictionary.com)
  • Prothrombin thrombophilia is an inherited disorder of blood clotting. (medlineplus.gov)
  • Most people with prothrombin thrombophilia never develop abnormal blood clots, however. (medlineplus.gov)
  • Some research suggests that prothrombin thrombophilia is associated with a somewhat increased risk of pregnancy loss (miscarriage) and may also increase the risk of other complications during pregnancy. (medlineplus.gov)
  • It is important to note, however, that most women with prothrombin thrombophilia have normal pregnancies. (medlineplus.gov)
  • Prothrombin thrombophilia is the second most common inherited form of thrombophilia after factor V Leiden thrombophilia . (medlineplus.gov)
  • Approximately 1 in 50 people in the white population in the United States and Europe has prothrombin thrombophilia. (medlineplus.gov)
  • Other factors also increase the risk of blood clots in people with prothrombin thrombophilia. (medlineplus.gov)
  • Pelzer, H. and Stuber, W., "Detection of Prothrombin Activation Fragments F.sub.2 /F.sub.1+2 by an Antibody Against a Synthetic Peptide," Haemostasis 1988, 18 Suppl. (freepatentsonline.com)
  • 1. A monoclonal antibody and fragments thereof that specifically bind to an epitope on the carboxy terminus of a prothrombin activation peptide, wherein said epitope comprises the amino acid sequence -Ser-Asp-Arg-Ala-Ile-Glu-Gly-Arg-OH, and wherein said monoclonal antibody is secreted by the hybridoma identified as ATCC No. HB 10291. (freepatentsonline.com)
  • 5. A method of immunologically assaying for prothrombin activation peptide F1.2 in a sample, comprising an immunoassay wherein a monoclonal antibody according to claim 1 is used as the capture antibody and wherein the immunoassay is a method selected from the group consisting of competitive inhibition immunoassays, single step immunoassays and agglutination immunoassays. (freepatentsonline.com)
  • 6. A diagnostic kit for immunologically assaying for prothrombin activation peptide F1.2 in a sample comprising a monoclonal antibody according to claim 1 coated on a solid phase. (freepatentsonline.com)
  • 7. A diagnostic kit for immunologically assaying for prothrombin activation peptide F1.2 in a sample comprising a monoclonal antibody derived from the hybridoma identified as ATCC No. HB 10291. (freepatentsonline.com)
  • To determine whether the prothrombin A 20210 allele is independently associated with the occurrence of venous thrombosis. (annals.org)
  • Factor VII has a short half-life and the carboxylation of its glutamate residues requires vitamin K. The prothrombin time can be prolonged as a result of deficiencies in vitamin K, warfarin therapy, malabsorption, or lack of intestinal colonization by bacteria (such as in newborns). (wikipedia.org)
  • Vitamin K is needed to make prothrombin and other clotting factors. (healthwise.net)
  • Actinomycin D inhibits vitamin K induced formation of prothrombin in chicks deficient in vitamin K. The administration of actinomycin in doses which inhibit prothrombin formation also inhibits synthesis in the liver of RNA from adenosine triphosphate as detected with adenine-8-C1 4 . (sciencemag.org)
  • Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy. (lu.se)
  • A one-stage prothrombin assay which measures the exponential rate of thrombin production in thromboplastin-treated, recalcified plasma. (google.com)
  • These images are a random sampling from a Bing search on the term "Prothrombin Time. (fpnotebook.com)
  • Prothrombin time is also useful in monitoring the effects of the blood-thinning medication warfarin. (rchsd.org)
  • The warfarin dose is changed so that the prothrombin time is longer than normal (by about 1.5 to 2.5 times the normal value or INR values 2 to 3). (healthwise.net)
  • Prothrombin time tests may also be ordered to look for causes of abnormal bruising or bleeding, check liver function or look for a bleeding disorder. (reference.com)
  • An abnormal prothrombin time is often caused by liver disease or injury or by treatment with blood thinners. (healthwise.net)
  • The following Beloc Prothrombin Time Abnormal side effect reports were submitted by healthcare professionals and consumers. (patientsville.com)
  • This information will help you understand how side effects, such as Prothrombin Time Abnormal, can occur, and what you can do about them. (patientsville.com)
  • This Prothrombin Time Abnormal side effect was reported by a health professional from SWITZERLAND. (patientsville.com)
  • and developed a serious reaction and a Prothrombin Time Abnormal side effect. (patientsville.com)
  • Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies includin. (nih.gov)
  • Merriam-Webster.com Medical Dictionary , Merriam-Webster, https://www.merriam-webster.com/medical/prothrombin%20time. (merriam-webster.com)